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Background: Mild Cognitive Impairment (MCI) is a clinical construct reputed to 
represent an intermediate stage on a continuum between normal aging and cognitive 
decline. Conceptual and prognostic ambiguity can lead to significant diagnostic 
challenges and there is a need for accurate screening tests which can assist clinicians 
with decision-making. A diagnosis of MCI is also associated with considerable 
uncertainty for patients who may be adjusting to cognitive difficulties along with an 
increased risk of developing dementia. Beliefs about MCI may influence psychosocial 
adjustment, and individual differences in ‘psychological flexibility (PF)’, as 
conceptualised by the Acceptance and Commitment Therapy (ACT) model, may also 
be involved in this process.  
Objectives: In order to evaluate the accuracy and clinical utility of a recently 
developed screening tool for MCI, the Montreal Cognitive Assessment (MoCA), a 
systematic review of validation and diagnostic test accuracy (DTA) studies for this 
measure was conducted. Psychosocial adjustment to a diagnosis of MCI was also a 
key focus. An empirical study was therefore carried out with the aim of evaluating the 
possible relationships between cognitive impairment, illness representations about 
MCI, psychological wellbeing and quality of life (QoL), and to assess the potential 
involvement of PF. 
Method: Following a systematic search of relevant electronic databases and reference 
lists, validation and DTA studies of the MoCA were identified and evaluated for 
methodological quality. For the empirical study, patients recently diagnosed with MCI 
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were recruited from local NHS memory clinic services and completed the MoCA and 
a questionnaire pack assessing illness representations, PF, mood, anxiety and QoL.  
Results: The systematic review identified 18 validation and DTA studies. Few of the 
studies achieved high ratings for methodological quality and problems with 
representativeness and generalisability were identified. Nevertheless, sensitivity levels 
appeared robust across studies, though specificity was variable. For the present 
empirical study, participants reported a spectrum of positive and negative beliefs about 
MCI. Distress attributed to MCI was associated with anxiety, along with perceptions 
of more serious illness consequences, while higher PF was associated with higher 
perceived QoL and mood. Lived experience of MCI appeared to have more relevance 
to psychosocial adjustment than objective cognitive impairment. 
Conclusions: The results of the systematic review indicate that while the MoCA is a 
robust tool overall in the identification of cognitive impairment, estimates of accuracy 
may be exaggerated by inter-study variation and bias. More rigorous validation studies 
are therefore needed. Implications for clinical decision-making regarding MCI are 
discussed and recommendations for future accuracy studies are outlined.  
The empirical study supported the findings of previous studies of the relevance of 
illness representations to psychosocial adjustment in MCI and added to the evidence 
base by providing preliminary support for the possible involvement of PF. The results 
suggest that both cognitive content and PF may represent possible vehicles for 
therapeutic change in patients with adjustment difficulties, and indicate that further 
investigation of these factors is warranted. Conclusions are limited, however, by small 
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sample size and low statistical power. Replication of these findings with a larger and 





























Title: The accuracy and clinical utility of the Montreal Cognitive Assessment in the 
screening and diagnosis of mild cognitive impairment: A systematic review 
Running title: Diagnostic test accuracy of the MoCA 
 
Authors: 
Amanda Stevenson, Trainee Clinical Psychologist, Clinical Psychology, School of 
Health in Social Science, University of Edinburgh  
Dr. David Gillanders, Academic Director (DClinPsychol), Clinical Psychology, 
School of Health in Social Science, University of Edinburgh 
Dr. Nuno Ferreira, Lecturer, Clinical Psychology, School of Health in Social Science, 
University of Edinburgh 
 
Corresponding author: Amanda Stevenson, Trainee Clinical Psychologist, 
Clinical Psychology, School of Health in Social Science, Old Medical School, Teviot 
Place, University of Edinburgh. 
Email: Amanda.Stevenson3@nhs.net 
 
Author contributions: Amanda Stevenson designed and conducted the review 
under the academic supervision of Dr. David Gillanders and Dr. Nuno Ferreira, who 
assisted with the design and research question and provided comments on the final 
manuscript. 
Word count (excluding tables, figures and references): 4,735 
 
This systematic review was prepared in accordance with the author specifications for 






The diagnosis of mild cognitive impairment (MCI) is associated with significant 
challenges. There is therefore recognition of the need for effective screening measures. 
The Montreal Cognitive Assessment (MoCA) is a recently developed tool which has 
grown in usage. The current review examines the available evidence for the diagnostic 
accuracy of the MoCA for people with MCI in clinical settings and evaluates its utility 
as a screening tool. 
Methods:  
Relevant electronic databases were systematically searched from April 2005 to 
February 2014 to identify suitable papers meeting inclusion and exclusion criteria. 
Reference lists were also hand searched. The methodological quality of included 
studies was evaluated using an adapted assessment checklist. 
Results:  
Inclusion and exclusion criteria were met by 18 studies. Most reported high levels of 
sensitivity for the MoCA, while specificity was more limited. There was substantial 
variability in quality ratings overall, with few studies achieving highly on the 
methodology domain. Population representativeness and generalizability was limited 
across studies. Reporting quality was generally poor, restricting assessment of the 





The MoCA appears to be a psychometrically robust tool in the identification and 
diagnosis of MCI despite cultural, language and methodological variation between 
studies. Areas of potential bias in study design may have exaggerated estimates of 
accuracy, however. More rigorous research evidence with representative population 
samples is therefore recommended.  
Key words: dementia; diagnostic accuracy; mild cognitive impairment; Montreal Cognitive 




Mild cognitive impairment 
There has been considerable debate in recent years regarding the etiology, presentation 
and prognosis associated with mild cognitive impairment (MCI). A meta-analysis of 
longitudinal studies reported varying outcomes from dementia diagnosis to 
maintenance of cognition and functioning, and even improvement1. Many longitudinal 
studies vary in length of follow up, however, and by inclusion of different MCI 
subtypes, argued to represent different disease trajectories2. MCI is typically classified 
into amnestic and non-amnestic subtypes, which can be further differentiated into 
single and multidomain profiles of impairment. Thus, various factors may affect both 





Despite disagreement whether MCI represents prodromal dementia, it is generally 
acknowledged that this diagnostic label confers an increased risk of developing 
Alzheimer's disease (AD) and other dementias2,3. The heterogeneity of MCI, combined 
with the lack of an official 'gold standard' for diagnosis and considerable variability in 
how the term is measured and applied4, has led to controversy regarding its conceptual 
utility, and it is accordingly associated with significant diagnostic challenges. 
Therefore, the development of accurate assessment and screening tools has been a key 
research imperative in recent years.     
 
Cognitive screening 
While various cognitive screening measures for memory and cognitive complaints 
have been developed, the Mini-Mental State Examination (MMSE)5 is perhaps the 
most widely used6. Despite a recent meta-analysis reporting high levels of sensitivity 
and specificity for dementia across a broad range of settings7, work by Wind et al.8 
suggested that the MMSE possessed limited value in identifying 'minimal' dementia. 
Indeed, Mitchell7 also concluded that there was little evidence for the efficacy of the 
MMSE with MCI. Nasreddine and colleagues9 further argued that the MMSE was 
susceptible to ceiling effects for milder cognitive difficulties. Thus, the MMSE 
potentially gives rise to significant numbers of false negative cases.  
 
Nasreddine et al.9 developed an alternative tool, the MoCA, for patients unlikely to be 
accurately identified by the MMSE. The MoCA was designed with reference to MCI 
neuropsychological profiles and covers eight cognitive domains, including memory, 
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visuospatial ability, language, attention and executive functioning. The MMSE in 
comparison has less emphasis on the latter two domains and contains items with lower 
difficulty. A cut-off of 26 or above across all domains on the MoCA is considered to 
be within the normal range, with an additional point added for people with 12 years of 
education or less.  
 
Koski et al.10 have reported that the MoCA provides an accurate quantitative 
measurement of cognitive functioning in MCI in outpatient settings, and a number of 
studies have reported the MoCA to be superior to the MMSE in identifying MCI11. 
High levels of sensitivity and specificity have been shown across both clinical12 and 
community settings13, and with selected populations, such as Huntington’s disease14. 
Studies of diagnostic and screening tools are vulnerable to bias and imprecision, 
however, which may give rise to unreliable estimates of a test’s performance15. There 
is therefore a need to systematically evaluate the accuracy of such tools and their 
efficacy in clinical practice.   
 
Diagnostic accuracy 
Diagnostic test accuracy (DTA) denotes the capacity of a measure, or index test, to 
differentiate between patients with and without a target condition, and typically 
compares the performance of the test against an agreed reference standard. The target 




The most frequently used statistical summary of DTA is a test’s sensitivity and 
specificity at clinical cut-off16, or the ability to identify true positive and true negative 
cases respectively. Many studies use the Receiver Operating Characteristic Area under 
the Curve (ROC AUC) statistic which summarizes sensitivity and specificity levels 
across varying test thresholds, with values closer to 1.0 representing higher accuracy17. 
Additional predictive statistics can also be calculated, including positive (PPV) and 
negative predictive values (NPV) which are based on epidemiology, and positive 
(LR+) and negative (LR-) likelihood ratios which estimate a patient’s likelihood of 
having or not having the condition based on their score. These statistics vary in their 
applicability to the interpretation of individual test results, however, and can be 
influenced by multiple artefactual and clinical factors18. Two common sources of bias 
in DTA studies include: target condition prevalence (spectrum bias), which can include 
use of selected populations, such as Parkinson’s disease, and the procedures used to 
confirm disease presence or absence (verification bias). Experimental imprecision can 
also contribute to inaccuracy, such as via index test or reference standard execution19.  
 
Screening tools such as the MoCA should not be used for diagnosis in isolation; 
however, DTA data can provide an assessment of the robustness of these measures and 
can assist diagnostic decision-making. It is therefore important to consider the quality 






Systematic review objectives 
This review considers the available literature on the MoCA with the following 
objectives: 
 To evaluate MoCA DTA in classifying patients with MCI. 
 To examine MoCA utility in assisting with clinical decision-making. 
 
Materials and Methods 
 
Search Strategy 
Systematic searches of the following electronic databases were conducted: EMBASE, 
Medline, PsychINFO, Web of Science, Scopus and ASSIA. Reference lists of included 
studies were also searched. The extant literature was initially scoped and search terms 
(Table 1) developed with reference to common key words. Since the original 
validation study for the MoCA was published in 2005, the search was restricted from 
April 2005 to February 2014. Following search completion, titles and abstracts were 
initially screened to remove studies not meeting inclusion criteria. The remaining 









Table 1 Electronic database search criteria: EMBASE, Medline, PsychINFO, Scopus and 
ASSIA 
Search terms 
 Montreal Cognitive Assessment 
 MoCA 
 Mild Cognitive Impairment 
 MCI 
 Dement* 




 1 or 2 
 3 or 4 or 5 or 6 
 7 or 8 or 9 
 10 and 11 and 12 
 
 
Inclusion and exclusion criteria 
Studies were screened against the following criteria: 
Inclusion criteria: 
 EITHER studies evaluating MoCA DTA for MCI OR Validation studies of the 
MoCA for MCI. 
 Studies aiming to evaluate the MoCA as a tool for differentiating between MCI 
and no cognitive impairment (NCI) or dementia. 
 Studies based in clinical settings, e.g., memory clinics, geriatric outpatient and 
inpatient departments, and primary care. 
 
Exclusion criteria: 
 Articles not in English 
 Studies including the MoCA as part of a wider assessment protocol, or as 
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comparator to another index test. 
 Editorials, conference posters, theses, review articles, guides and letters. 
 Studies investigating selected clinical populations, e.g., Parkinson's disease. 
 
Assessment of methodological quality 
No existing standardized tool was considered to sufficiently cover the key quality 
determinants for administration, interpretation and analysis of the MoCA for MCI. An 
assessment tool was therefore developed and adapted from the following standardized 
checklists: the QUADAS tool20, Scottish Intercollegiate Guidelines Network (SIGN) 
Methodology Checklist 5 for DTA studies21, and STARD guidelines for reporting of 
diagnostic studies22. The final assessment tool is presented in Figure 1 and has a total 
score of 20 derived from the following domains: abstract and introduction (2 points); 
methodology (10 points); results and discussion (8 points). Each item was coded 
according to operational criteria developed by the first author (AS) using the following 
ratings: Yes=1, No=0 Unclear=0. The full list of operational criteria for each item are 
presented in Appendix A1. All papers were evaluated by the first author. A subset of 
6 studies was co-rated by an independent practitioner. Identification of papers for co-
rating was based on overall score following initial rating by the first author and was 
selected so that a range of high, mid and low scoring studies were represented. Inter-
rater reliability was fair at 68.3%. Where discrepancies were identified, these were 





Figure 1 Quality assessment tool 
CHECKLIST FOR DIAGNOSTIC ACCURACY 




Yes – 1 
No/Unclear – 0 
Item Score 
Abstract and Introduction  
1. Abstract identifies the article as a diagnostic accuracy study, and clearly reports study methodology, 
results and conclusions 
 
2. Introduction clearly outlines the research question(s) and/or study aim(s)  
Total    /2 
Methodology  
3. The methods of recruitment of the study population are appropriate  
4. The study population is representative of the patients who would typically receive the test in 
practice 
 
5. The reference standard and its execution are appropriate (i.e. likely to correctly classify the target 
condition) 
 
6. The number and expertise of the persons executing and interpreting the reference standard would be 
considered appropriate 
 
7. The index test version and its execution would be considered appropriate  
8. The number and expertise of the persons executing and interpreting the index test would be 
considered appropriate 
 
9. All participants receive the same reference standard  
10. The index test results were interpreted without knowledge of the reference standard results  
11. The reference standard results were interpreted without knowledge of the index test results  
12. Index test results were interpreted according to a pre-determined cut-off  
Total /10 
Results and discussion   
13. Any withdrawals or exclusions from the study were explained  
14. Statistical methods used to calculate and/or compare measures of diagnostic accuracy were 
appropriate 
 
15. The results of statistical methods used to assess diagnostic accuracy were reported in full  
16. Clinical and demographic characteristics of the study population were clearly reported and any 
differences were accounted for in statistical analysis 
 
17. Index tests scores were appropriately adjusted for education level  
18. Estimates of diagnostic accuracy included measures of statistical uncertainty (e.g. 95% confidence 
intervals)  
 
19. Optimal cut-off values were calculated and reported  
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20. The clinical applicability of the study findings was discussed  
Total /8 





Outcome of search process 
This process is summarized in Figure 2. Electronic databases were searched on 19th 
February 2014, with 1165 studies retrieved. A further 10 studies were identified from 
study reference lists. Following de-duplication, 655 studies remained for screening of 
titles and abstracts. Review of titles excluded 448 studies, while 155 were excluded at 
abstract level. A total of 52 studies were read in full and assessed for eligibility using 
a data extraction form adapted from an existing tool developed by the Cochrane 
Collaboration23. After removing 34 studies, a final group of 18 studies was judged to 


















Study demographic information is presented in Table 2. Studies differed by country of 
origin, entailing significant variation in both translations of the MoCA and in 
numerous culturally-dependent items. In addition, studies varied in inclusion of MCI 
subtypes, with seven studies recruiting amnestic-MCI (aMCI) participants only. There 
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was also marked variation in sample sizes, with the number of MCI participants 
ranging from 2324 to 15025. Razali et al.26 was the only study without a comparison 
group. The remainder of studies recruited participants with dementia, typically AD, 
and NCI participants. Most studies incorporating an NCI group restricted inclusion 
criteria to those with no subjective or objective memory complaints; however, Smith 
and colleagues’24 comparison group comprised memory clinic attendees with other 
cognitive complaints. The majority of studies used Petersen et al.3 MCI criteria 
supported by clinical diagnosis, while Lifshitz et al.27 used alternative appropriate 
criteria outlined by Busse et al.28 and Winblad et al.29, along with a computerized 
cognitive battery and clinical diagnosis. Overall, studies tended not to include 
participants over the age of 80, which may limit applicability of the MoCA with a 
significant proportion of older adults. 
 
Quality assessment of studies 
Methodological review 
A summary of ratings for each study is presented in Table 3, with studies listed in 
order of overall score. The studies scoring highest on the rating tool were Luis et al.12 
, followed by Memoria et al.30, Smith et al.24 and Lee et al.31 . The lowest scoring 
studies were Duro et al.32 and Lifshitz et al.27. Notably, however, there was high 
variability in methodology domain scores across studies, with only five meeting 50% 
or more of criteria. Therefore, overall scores cannot be considered an accurate 




Table 2: Study demographic information 
Study MoCA 
version 
Aim MCI Reference 
Standard 
Participants Males Age (SD) Years of education 
(SD) 
Mean MoCA score 
(SD) 
Luis et al.12 English Validation; 
DTA 












78.9 (5.3) aMCI 
79.9 (4.3) AD 
78.9 (3.7) NCI 
14.4 (4.1) aMCI 
13.5 (2.6) AD 
14.2 (2.5) NCI 
20.5 (2.4) aMCI 
15.8 (6.5) AD 





Petersen et al.3; 
CCD: 








74.3 (5.6) MCI 
76.53 (4.87) AD 
71.68 (4.62) NCI 
11.41 (4.23) MCI 
11.1 (5.01) AD 
13.41 (4.45) NCI 
22.64 (2.83) MCI 
16.42 (3.85) AD 
26.3 (2.61) NCI 
Lee et al.31 Korean Validation; 
DTA 










71.3 (5.9) MCI 
70.4 (8.6) AD 
69.1 (6.1) NCI 
8.3 (3.8) MCI 
7.9 (3.7) AD 
8.0 (3.5) NCI 
18.5 (3.7) MCI 
12.9 (5.0) AD 
















77.5 (7.8) MCI 
74.4 (9.3) Dementia 
64.0 (10.8) MCC 
11.3 (2.5) MCI 
12.7 (2.5) 
Dementia 
12.0 (2.5) MCC 
22.5 (3.5) MCI 
21.0 (3.4) Dementia 






















68.5 (6.5) sd-MCI 
71.1 (11.3) md-MCI 
76.3 (8.5) dementia 
62.8 (9.9) NCI 
8.5 (4.2) sd-MCI 
6.4 (4.8) md-MCI 
4.7 (4.5) dementia 
9.4 (3.9) NCI 
22.4 (3.0) sd-MCI 
15.2 (5.2) md-MCI 
11.2 (4.8) dementia 
24.9 (3.0) NCI 













60.7 (5.0) MCI 
68.4 (4.3) AD 
67.2 (5.3) NCI 
9.82 (3.0) MCI 
8.9 (3.1) AD 
9.3 (2.6) NCI 
24.5 (1.9) MCI 
17.2 (5.5) AD 















77.3 (6.3) MCI 
77.5 (6.0) AD 
76.4 (3.3) NCI 
11.5 (3.1) MCI 
12.1 (3.0) AD 
12.3 (2.3) NCI 
--  
-- 
--   












62.43 (9.4) aMCI 
72.58 (7.15) AD 
56.35 (8.27) NCI 
10.93 (4.28) aMCI 
6.97 (4.47) AD 
12.07 (3.2) NCI 
27.0 (3.07) aMCI 
20.8 (4.06) AD 


















72.29 (8.12) MCI 
75.69 (8.21) AD 
71.19 (9.2) NCI 
 
14.86 (4.2) MCI 
13.33 (4.15) AD 
15.91 (3.03) NCI 
20.94 (4.5) MCI 
13.04 (6.05) AD 
26.83 (2.64) NCI 
Zhao et 
al.25 










70.67 (4.27) aMCI 
69.85 (5.21) NCI 
-- 
-- 
20.5 (1.) aMCI 
25.5 (2.3) NCI 
Chu et al.38 Cantonese Validation; 
DTA 
Petersen et al.3; 







77.2 (6.3) aMCI 
78.5 (5.8) AD 
72.2 (6.1) NCI 
4.62 (5.19) aMCI 
4.56 (5.0) AD 
6.97 (4.69) NCI 
18.7 (4.6) aMCI 
11.3 (5.1) AD 
















75.19 (6.27) MCI 
76.72 (8.83) AD 
72.84 (7.03) NCI 
12.28 (4.32) MCI 
10.03 (3.84) AD 

























70.52 (7.95) aMCI 
74.22 (8.21) AD 
69.59 (7.05) C-aMCI 
73.10 (7.54) C-AD 
6.5 (4.57) aMCI 
6.23 (4.12) AD 
6.53 (4.5) C-aMCI 
6.24 (4.13) C-AD 
18.31 (3.87) aMCI 
10.06 (4.41) AD 
23.64 (3.22) C-aMCI 




AD: Alzheimer’s disease; aMCI: amnestic mild cognitive impairment; Biochem: biochemical data; CD: clinical diagnosis; CCD: consensus clinical diagnosis; CDR: 
Clinical Dementia Rating Scale42; CFA: Confirmatory factor analysis; DTA: diagnostic test accuracy; md-MCI: multi-domain mild cognitive impairment; sd-MCI: 








Not specified 180 memory 
clinic attendees 
With MCI: 49 
 
Median age: 
With MCI 65.3  
Without MCI  62.5 
Median education: 
With MCI 6 
















67.8 (8.13) MCI 
71.07 (8.57) AD 
65.4 (9.26) NCI 
11.47 (2.85) MCI 
10.60 (2.42) AD 





Tsai et al.41 Taiwanese Validation; 
DTA 












79.2 (6.8) aMCI 
79.6 (6.4) AD 
77.7 (6.0) NCI 
8.9 (5.1) aMCI 
8.4 (4.9) AD 
10.1 (4.4) NCI 
20.5 (4.0) aMCI 
12.6 (5.2) AD 





Petersen et al.3; 
CDR; 


























20.3 (3.31) MCI 
26.73 (1.94) NCI 
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Luis et al. 12 + + - - + + + ? ? + + + + + - + + + + +     
Memoria et al.30 + + ? - + + ? + + + + + + ? - - + + + +     
Lee et al.31 + + ? - + + + - ? + + ? + + + + ? + + +     
Smith et al.24 + + + - + ? ? ? + + ? - + + + + + + + +     
Dong  et al.11 + + + - + + ? ? + + + ? - + - - + + + +     
Hu et al.34 + - - - ? + ? ? ? + ? + + + + + + + + +     
Fujiwara et al.35 + + - - + ? + ? ? ? ? ? + + + + ? + + +     
Ng et al.36 + + - - + ? ? ? ? ? + + + + - + + - + +     
Roalf et al.37 - + + ? + ? ? ? ? + + ? + + - - ? + + +     
Zhao et al.25 - - - - + + - ? ? + + ? + + + + ? + + -     
Chu et al.38 + + - - + ? + ? + ? ? ? + + - ? + - + +     
Nasreddine et al.9 + + - - + ? ? ? - ? + + + + - - + - + +     
Freitas et al.39 + + - - + ? - - - ? + ? - + - + + + + +     
Razali et al.26 - + + - - ? + ? ? ? ? + + - - + + + - +     
Costa et al.40 - + - - + ? - - ? ? + ? + + - + ? + + +     
Tsai et al.41 + + - - + ? + ? ? ? ? - ? + - + ? + + +     
Duro et al.32 ? + - - + ? ? ? + ? ? + + - - ? + - - -     
Lifshitz et al.27 + ? - - + ? ? ? - ? ? + + + - - ? - - +     
Items 1-20 correspond with Figure 1. + = Yes; - = No; ? = Unclear
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No study was judged to have evaluated a representative population. All studies using 
case-control methodology failed to meet this criterion since patients without subjective 
memory or cognitive complaints would be unlikely to receive the MoCA in practice. 
The two studies which did not use this design, Dong et al.11 and Razali et al.26 were 
considered to have employed restrictive inclusion and exclusion criteria which limit 
external validity. Similarly, most studies did not use appropriate recruitment methods, 
or did not sufficiently report methodology. Only Dong et al.11, Razali et al.26, Roalf et 
al.37 and Smith et al.24 reported recruiting all participants from a clinical setting, though 
the latter two studies subsequently employed a case-control design, limiting the 
representativeness of their sample.   
 
Overall methodology reporting was poor. Various areas were consistently omitted, 
including the number and expertise of individuals executing and interpreting the 
MoCA, MoCA administration, reference standard application, independence of 
reference standard and MoCA outcomes and use of pre-determined MCI cut-offs. 
Where these factors were addressed, some studies did not meet quality criteria. Only 
Memoria et al.30 clearly specified an appropriate number of people with sufficient 
expertise to administer and interpret the MoCA. Two studies did not outline 
appropriate execution, with the MoCA test being administered immediately following 
the MMSE. Performance on the MMSE may have influenced interpretation of the 
MoCA, and thus confirmation bias cannot be fully discounted. Three studies reported 
that not all participants received the same reference standard; thus, some participants 
were more highly investigated than others. One study did not use a pre-determined cut-
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off, increasing the likelihood of confirmation bias. Considering the above factors, the 
potential for verification bias also cannot be excluded. 
 
Statistical analysis and interpretation 
Three studies did not state clear objectives in their introduction. Judgment of the 
suitability of their statistical analysis is therefore limited. In addition, Memoria et al.30 
did not clearly report the statistics used in their DTA analysis. Duro et al.32 and Razali 
et al.26 did not meet criteria for appropriate statistical analysis. Both studies reported 
only one DTA measure. Thirteen studies did not fully report DTA results, many 
providing only optimal sensitivity and specificity figures without presenting the full 
range of thresholds. Few studies calculated PPV, PNV or probability data. Comparison 
of DTA across studies is therefore compromised. Five studies did not consistently 
report measures of statistical uncertainty. Thus, assessment of the reliability of their 
DTA data is restricted. 
 
Reporting of demographic information was also variable. Some studies noted 
significant between-group differences in age and education level which were not 
subsequently accounted for in their analysis of MoCA scores. Increased age and lower 
educational levels have been associated with poorer MoCA performance40. This 
suggests that demographic discrepancies may explain some of the between-group 




The appropriateness of adjustments to scores by educational level were unclear for 
seven studies, making it difficult to evaluate the possible impact of this on DTA results. 
Gagnon et al.43 found that overall sensitivity, specificity and optimal cut-off scores on 
the MoCA were significantly altered when scores were corrected for education level. 
 
Diagnostic accuracy 
Table 3 presents a summary of DTA statistics across all studies, including LRs based 
on available sensitivity and specificity data. It was not possible to calculate PPVs and 
NPVs due to the variation in available base-rate data for MCI in each country. 
 
Sensitivity levels were high overall, ranging from 0.7725 to 1.0040 while specificity 
levels were more variable, ranging from 0.1936 to 1.035. This likely relates to the 
diverse methodological differences between studies, variation in reported optimal cut-
offs and the ethnic, cultural and educational differences between included populations.  
 
All studies apart from Smith et al.24, Ng et al.36, Nasreddine et al.9 and Duro et al.32 
calculated the ROC AUC. Reported AUC values were high across all studies, ranging 
from 0.8226,30 to 0.9712. ROC curves can be used to compare results from multiple 
studies; however, since not all studies reported sensitivity and specificity at varying 




Where possible, LR+ and LR- were calculated from reported sensitivity and specificity 
values. When LR+ is greater than 1, people with the target condition are more likely 
to score in the positive range, and when LR- is greater than 1, people with the target 
condition are more likely to score in the negative range44. LR+ values varied markedly, 
ranging from 1.1636 to 44.531, while LR- values ranged from 040 to 0.3424. This means 
that scores on the MoCA were generally likely to deliver an accurate diagnostic 
conclusion. Interestingly, data reported by Luis et al.12 and Lee et al.31, both of which 
scored among the highest on the quality rating tool, resulted in notably large LR+ 
values. Both studies used small sample sizes with limited representativeness, however. 
Nevertheless, these figures suggest that the MoCA may produce more robust 












Cut-off Sensitivity Specificity AUC LR+ LR- 
Luis et al.12 English 23† 0.96 0.95 0.97 19.2 0.04 
Memoria et 
al30 
Brazilian 26 0.91 0.56 0.82 2.07 0.16 
Lee et al.31 Korean 22/23 0.89 0.98 0.94 44.5 0.11 
Smith et al.24 English 26 0.83 0.50 –  1.66 0.34 
Dong et al11 Chinese 
Malay 
19/20‡ 0.83 0.86 0.95 5.93 0.20 
Hu et al.34 Chinese 26 0.92 0.85 0.93 6.13 0.09 
Fujiwara et 
al.35 
Japanese 25/26 0.93 1.00 0.95 N/A
¶ 0.07 
Ng et al.36 English  
<10 years education: 26† 
 






















Roalf et al.37 English 25 0.84 0.79 0.89 4.00 0.20 
Zhao et al.25 Chinese 23/24† 0.77 0.90 0.88 7.70 0.26 





26 0.90 0.87 –  6.92 0.11 
Freitas et al.39 Portuguese 22† 0.81 0.77 0.86 3.52 0.25 
Razali et al.26 Bahasa- 22/23 –  –  0.82 –  –  




  aComparison between a-MCI and NCI;  bComparison between md-MCI and NCI; cComparison between MCI and dementia; dRatio 
undefined due to denominator value of zero.  
Malaysian 
Costa et al.40 German MoCA 1: 26 

















Tsai et al.41 Taiwanese 23/24† 0.92 0.68 0.91 2.88 0.12 
Duro et al.32 Portuguese 26
§ 0.84 1.00 –  N/A
¶ 0.16 





Findings from current review 
Diagnostic accuracy 
Using a structured and comprehensive search strategy, 18 studies reporting 
psychometric properties and DTA statistics for the MoCA with MCI were identified. 
Sensitivity levels were consistently high and similar to that of the original validation 
study, supporting its efficacy in detecting ‘true’ MCI in line with the authors’ aims. 
Specificity was more modest, indicating that the MoCA may give rise to significant 
numbers of false positive cases. Comparisons of ROC AUC values showed that the 
MoCA performed similarly well across all included studies. Calculated LRs indicate 
that people with MCI are likely to score positively on the MoCA while people with 
NCI are likely to score negatively. These figures suggest that the MoCA is a robust 
screening tool for MCI. 
 
Quality assessment 
Only five studies met 50% or more of quality criteria for the methodology domain, 
however, and there was significant variability in ratings across studies and domains. 
Thus, total scores are not considered to be a proxy of study quality. The majority of 
studies used case-control methodology, and all used populations not considered 
representative of memory clinic or geriatric outpatient attendees. Many studies did not 
fully report methodology or the results of statistical analysis, a significant number 
calculating only limited DTA statistics. Some areas of possible bias were identified, 
including spectrum and verification bias. Between-group demographic differences in 
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age and education were common, but the possible influence of these on MoCA 
performance was not always evaluated. The relationship between methodological 
quality domain scores and reported DTA also appears variable, with no consistent 
pattern identified. Studies with both high and low quality ratings published DTA data 
which was suggestive of high accuracy, suggesting that any conclusions drawn would 
be of limited reliability. 
 
Limitations of DTA studies 
MCI prevalence 
Target condition prevalence within an included sample can significantly influence 
DTA findings19. Therefore an artificial patient spectrum can lead to inaccuracies in the 
assessment of a test’s efficacy. Unrepresentative samples can arise through spectrum 
bias and experimental variability. Case-control methodology, in addition to restrictive 
inclusion and exclusion criteria, can inflate disease prevalence. This is particularly 
problematic where sample sizes are low, as was the case for numerous studies in the 
current review. Where participants known to have MCI are recruited separately to NCI 
participants, prevalence is skewed towards cases who would be easily identified by the 
index test, which could increase sensitivity estimates33. This risk is minimized, 
however, where all participants are sampled from the same setting, as with studies 
conducted by Smith et al.24 and Roalf et al.37, though their inclusion criteria stipulated 
a priori diagnosis. It must also be noted that clinical settings will likely reflect a higher 




Additionally, excluding other clinical presentations which might meet some MCI 
criteria, such as subjective memory complaints or psychiatric diagnoses, would not 
reflect the MoCA’s clinical use as a screening measure. Memory clinic or geriatric 
outpatient attendees may present with cognitive difficulties of varying etiologies; thus, 
for a cognitive screen to be clinically useful it must also demonstrate efficacy with 
ambiguous presentations. Furthermore, since defined MCI cases in included studies 
are necessarily subject to greater investigation, it is arguable that some excluded 
ambiguous cases might have been classed as MCI if they had received the reference 
standard. MCI diagnostic criteria would not necessarily restrict patients with 
psychiatric complaints from being classified thus; for example, major depression 
presentation in older adults can be associated with cognitive impairment45. Therefore, 
there may be unknown numbers of false negative cases in these studies. 
 
Reference standard and verification 
The conceptual elasticity of MCI leads to inherent difficulties in delivering precise and 
valid diagnoses. Petersen et al.’s 3 criteria is generally accepted and is extensively 
applied; however, the lack of an established 'gold standard' may result in inaccuracies 
and imprecision in deploying reference standard criteria in DTA studies. The majority 
of studies in the current review employed Petersen and colleagues'3 criteria, with 
supporting clinical, neuropsychological and neuroimaging data. Despite this general 
uniformity, studies varied in the number and expertise of diagnosing clinicians. This 
may have led to diagnostic variability and thus may have influenced reported MoCA 




Additionally, the extent to which patients undergo verification procedures can affect 
sensitivity and specificity. Partial-verification bias occurs where the reference standard 
is more likely to be applied to participants scoring above index test cut-off, a procedure 
that can inflate sensitivity15. Three studies in the current review reported that MCI and 
dementia patients received full diagnostic work-up while NCI participants were 
evaluated on less stringent criteria. Freitas et al.39 separately recruited patients with an 
established diagnosis, Lifshitz et al.27 used consensus diagnosis to confirm only 
cognitively impaired participants and Nasreddine et al.9 applied the reference standard 
to only a subset of their NCI participants. Since performance on the MoCA itself did 
not determine eligibility for verification, the involvement of bias may be minimized; 
however, patients with established MCI are more likely to score significantly on the 
MoCA. Several other studies did not clearly state that all participants received the 
reference standard, therefore bias cannot be fully discounted.  
 
Statistical analysis 
Few studies reported comprehensive DTA data. The majority summarized optimum 
sensitivity and specificity levels and reported ROC AUC figures. As noted above, 
these can depend on factors independent of index test efficacy and, given the 
methodological limitations of the studies in the current review, may not therefore be 
generalizable to clinical practice. Optimal cut-offs, while providing a trade-off 
between sensitivity and specificity, hinder comparison and consensus, particularly 
where there are also cultural and language differences between MoCA test versions. 
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The current review found that cut-offs also varied by adjustment for educational level, 
a necessary modification for populations with poor levels of literacy and education but 
which increases between-study inconsistency. Cross-cultural differences may be partly 
mitigated by reporting of PPVs and NPVs, since these rely on regional prevalence 
data46. Only seven studies reported these values, however.  
 
Quality of reporting 
Reporting standard was generally poor across all studies. Numerous core quality 
determinants were frequently omitted, including MoCA administration and rater 
expertise, the independence of MoCA and reference standard results, blanket 
application of the reference standard and use of pre-determined cut-offs. Absence of 
this information restricted quality assessment and likely resulted in some studies 
attaining a lower overall rating. Under-reporting also limits conclusions from DTA 
data since possible bias and measurement error is hidden. The STARD initiative22 was 
established to improve DTA study reporting and a corresponding assessment tool was 
developed. In the current review it was considered that studies with limited 
methodological quality might attain higher scores due to better reporting, and that this 
may skew quality assessment findings. Therefore, the emphasis of ratings was more 







Clinical utility of the MoCA 
The MoCA should not be used as a diagnostic test in isolation but in combination with 
physical, neurological, functional and neuropsychological data. Nevertheless, DTA 
analysis can be used to assess its efficacy in identifying patients requiring further 
investigation. DTA studies can facilitate clinical decision-making by providing 
parameters clinicians can apply to individual cases, evaluating test thresholds which 
are relevant to routine clinical practice, and reporting reliable and valid sensitivity and 
specificity values18.  
 
All studies in the current review provide DTA statistics of MoCA performance in 
detecting MCI, but a number of factors hinder interpretation of these figures. The 
nature and direction of identified bias and artefactual imprecision are likely to have 
increased sensitivity and decreased specificity. This means that the accuracy of the 
MoCA in identifying and correctly classifying ‘true’ MCI may be inflated, and that it 
could misclassify a significant proportion of false positives. Moreover, since 
sensitivities and specificities are frequently, but not always, reported for optimal cut-
offs, this leads to greater uncertainty regarding clinically significant thresholds. 
Differences in cut-offs may reflect MCI heterogeneity, but also likely relate to cross-
cultural and language differences. At present it seems no threshold can be universally 
applied, and thus judgment of individual MoCA scores lies with the administering 
clinician. Frequently, ROC AUC figures are also reported, which facilitate between-
test and between-study comparisons, but application in clinical practice is limited as 
the relevance of scores in individual cases cannot easily be extrapolated and they often 
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span cut-offs which are unrealistic18. In addition, the limited age ranges included in 
MoCA validation studies are likely to restrict the reliability of this cognitive screen 
with patients over the age of 80.   
 
Where supplementary DTA statistics are reported, these can assist the clinician with 
individual decision-making. Clinicians can judge the prospect of a person with MCI 
scoring positively, and a cognitively healthy person scoring negatively on a test using 
LRs. They are argued to be more clinically useful than sensitivity or specificity data 
since they do not change by patient or prevalence47. The applicability of LRs depend 
on accurate sensitivity and specificity estimates, however. PPVs and NPVs can also 
be useful in estimating the probability of MCI presence or absence on the basis of test 
score, but are contingent on knowledge of the base rate of MCI within a given 
population.  
 
Limitations of review 
This review included only articles written in English. The systematic search strategy 
identified 10 potential studies which did not meet this criteria and therefore could not 
be evaluated, representing a significant proportion of studies whose contribution to the 





Additionally, the inclusion of studies using translated versions of the MoCA, while 
ensuring that cross-cultural findings could be assessed, resulted in inherent restrictions 
in the comparison of results owing to modifications to the original measure, and 
population differences. Nevertheless, narrowing the focus of the review question 
would have led to a significant number of studies being omitted, as only five studies 
used an English version of the MoCA. 
 
Inter-rater agreement for the quality assessment tool in the current review was only 
fair, limiting its reliability; however, the highest levels of disagreement reflected areas 
where reported information was variable and unclear. Reporting quality also 
significantly affected the scope of the conclusions drawn in this review, with many 
studies attaining only low scores on the methodology domain due to lack of clarity 
regarding procedure. Thus, a further limitation of the current review is that authors 
were not contacted for further information which may have gone unpublished. Use of 




The accuracy of the MoCA in detecting ‘true’ MCI cases appears to be a robust finding 
across varying methodology, language, culture and ethnic background. Consistent 
reports of high sensitivity can give clinicians confidence in its use with this population 
ahead of other tests, such as the MMSE; however, this systematic review found 
evidence of potential inaccuracies in estimates of sensitivity across validation studies. 
Specificity rates are less favorable, but are also likely to be inaccurate. The impact of 
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this may be negligible in clinical practice as clinicians must frequently rely on 
subjective judgments of objective evidence when utilizing screening measures, 
especially where there may be a lack of conceptual clarity, as with MCI. Thus, 
diagnostic decisions should not be based wholly on evidence from such tests. Further 
investigation of identified cognitive difficulties should be enshrined within standard 
procedure. 
 
In summary, the MoCA has evident clinical utility as a screening measure for MCI; 
however the current applicability of its psychometric properties requires more rigorous 
validation. 
 
Implications for future research 
 
 Future studies should employ STARD guidelines when presenting results of 
DTA research to ensure appropriately informative and detailed reporting. 
 
 Validation studies should use appropriate sampling methods and should avoid 
use of case-control methodology. 
 
 All participants should receive the reference standard and be subject to the 




 Authors should give consideration to reducing potential bias in MoCA 
administration by employing appropriately trained clinicians and by ensuring 
that results of other tests do not influence its interpretation, either via the order 
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    Amended Aims 
 
The purpose of this brief section is to outline the recruitment difficulties encountered 
in the implementation of the study design and procedure, and the implications for the 
statistical analysis of the research questions. 
 
Original objectives 
A key aim of the study was to conduct mediational analysis in order to evaluate the 
possible mediatory role of a major construct in Acceptance and Commitment Therapy 
(ACT), ‘psychological flexibility’ (PF) in the relationships between independent and 
dependent variables associated with psychosocial adjustment to MCI. Power 
calculations were based on recommendations by Cohen (1992) for a power of 0.8 at α 
= 0.05, and by Fritz and Mackinnon (2007) for the appropriate sample size to detect 
the mediated effect. Using bias-corrected bootstrapping, a sample size of 53 was 
suggested on the basis of a medium magnitude pathway (0.39) between the 
independent variable and the mediator variable, and a large magnitude pathway (0.59) 
between the mediator variable and the dependent variable, on the expectation of a 
significant relationship between independent and dependent variables. These effect 
sizes were estimated from correlational data reported in previous studies with similar 
variables and populations (e.g. Ferenbach et al., 2011; Hurt et al., 2011). A sample of 
53 was judged to be achievable on the basis of previous service-wide data on referral 
patterns, which suggested that approximately 20-25% of patients referred to memory 
services over an 18 month period met criteria for MCI (Lonie et al., 2008). It was 
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Considerable recruitment difficulties were encountered following an unforeseen delay 
in the processing of the project ethics application, leading to a reduced recruitment 
period of 4 months. The number of people identified from case-file review across the 
health board region was also significantly lower than expected and there appeared to 
be widespread variation in how MCI was classified and recorded by clinicians. This 
may be related to the heterogeneity of MCI as a clinical population, and may reflect 
varying patterns of referrals from general practitioners (GPs), who may differ in their 
identification of patients requiring further assessment (Kaduszkiewicz et al., 2010). A 
total of 83 patients were identified, of which 23 did not meet inclusion and exclusion 
criteria. The remainder were approached via post and invited to opt in to the study, 
which was a condition of ethical approval. It is possible that this form of approach may 
have contributed to reduced levels of participation as it placed a higher demand on the 
memory abilities of patients with cognitive difficulties. In addition, few patients with 
MCI were referred from clinic appointments, with clinicians reporting that they did 
not tend to see patients with MCI outside of memory service pathways. 
 
Despite extending the length of the data gathering period, and widening study 
eligibility for people diagnosed with MCI within the past 9 months rather than within 




Implications and revised plan 
It was considered that the number of participants recruited would not give sufficient 
power for mediation analysis and that the unreliability of conducting this type of 
analysis with a small sample size may violate its statistical assumptions, thereby 
increasing the risk of both type-I and type-II errors. On this basis, it was decided that 
bivariate correlational analysis would be a more appropriate method to describe and 
test the associations between independent and dependent variables. The emphasis of 
study objectives was therefore altered to reflect this and the journal article was written 
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People with mild cognitive impairment (MCI) face various cognitive difficulties along 
with the considerable uncertainty posed by the increased risk of developing dementia 
in the future. Beliefs about MCI may play a role in psychosocial adjustment to this 
condition, but individual differences in ‘psychological flexibility’ (PF) may also be 
involved in this process.  
Objectives 
To assess the possible relationships between illness representations, cognitive 
impairment, PF and psychosocial adjustment variables in people with MCI. 
Method 
Nineteen older adults recently diagnosed with MCI were recruited from local NHS 
memory clinic services and completed measures assessing cognitive impairment, 
illness beliefs, PF, psychological wellbeing and quality of life (QoL) in this 
exploratory cross-sectional study. Associations between variables were tested using 
correlational analysis. 
Results 
 Participants reported both positive and negative appraisals about MCI. Negative 
emotional representations and perceptions of more serious consequences were 
associated with elevated anxiety, while higher PF was associated with more positive 
outcomes in mood and perceived QoL. The number of experienced MCI symptoms 
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appeared to be more associated with psychosocial adjustment than objective cognitive 
impairment.  
Conclusions 
Both PF and the content of illness beliefs may be relevant to psychosocial adjustment 
processes in MCI, though further research is needed to replicate these findings with a 
larger and more representative sample. 





Mild cognitive impairment (MCI) has emerged in both research and clinical practise 
as a classification which may represent an intermediate state of cognitive decline 
between normal aging and dementia. People with MCI are at increased risk of 
developing dementia, with estimated annual progression rates varying between 5% and 
12% (Mitchell & Shiri-Feshki, 2009; Petersen et al., 1999). This can vary, however, 
by setting, methodology, diagnostic criteria, or whether impairment is classed as single 
or multidomain. A recent meta-analysis of 41 cohort studies spanning up to 10 years 
reported that a significant proportion of MCI patients either remain cognitively stable 
or improve (Mitchell & Shiri-Feshki, 2009), giving rise to considerable uncertainty for 
both clinicians and patients. Thus, the usefulness of MCI as a clinical entity continues 




While there are no universally agreed guidelines for MCI classification, those 
suggested by Petersen and colleagues (1999) are commonly employed. These include 
subjective memory complaints underlined by objective evidence which does not meet 
criteria for dementia. Functional abilities are usually maintained. People with MCI 
therefore experience similar cognitive difficulties to people with dementia, but at 
attenuated levels. Currently, there are no available evidence-based treatments for 
patients with MCI in the UK (National Institute for Health and Care Excellence; NICE, 
2012), and there is little prognostic certainty for this clinical group. In addition, mood 
and anxiety difficulties are also prevalent in MCI populations compared with age-
matched control groups (Hwang, Masterman, Ortiz, Fairbanks & Cummings, 2008). 
Patients with MCI must therefore manage the practical and psychological 
consequences of cognitive problems without a clear explanation for their difficulties 
or a concrete disease trajectory. This may be viewed as a significant threat to health 
and wellbeing by people with MCI, both of which have implications for psychosocial 
adjustment processes. 
 
The Common Sense Model (CSM) of Illness Representations 
One proposed theoretical model of how people conceptualise and manage illnesses and 
health threats is the CSM (Leventhal et al., 1984 cited in Leventhal, Diefenbach & 
Leventhal, 1992). The model posits that individuals develop internal illness schemata 
based on information integrated from various sources, including concrete data 
gathered from health professionals or the media, their own understanding of 
symptoms, and others’ views and interpretations. These beliefs are said to influence 
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responsive coping behaviours and subsequently adjustment to the illness. Several core 
themes are considered to underlie these appraisals: illness chronicity, consequences, 
controllability, unpredictability and coherence, in addition to parallel emotional 
representations. The model hypothesises that negative appraisals trigger maladaptive 
ways of coping and are associated with lower perceived wellbeing. Numerous studies 
have investigated the CSM across different chronic physical health problems, finding 
broad support for the model (Hagger & Ornell, 2003; Petrie, Jago & Devcich, 2007). 
 
Various qualitative and quantitative studies (for a review see Dean & Wilcock, 2012) 
have explored the impact of MCI from the individual’s perspective. Frank et al. (2006) 
conducted focus groups with MCI and Alzheimer’s disease (AD) patients and their 
carers, highlighting themes such as: uncertainty about diagnosis, skill loss and negative 
emotions. Joosten-Weyn Banningh and Vernooij-dassen (2008) conducted semi-
structured interviews with MCI patients, noting similar concerns about the negative 
cognitive, physical and emotional consequences of MCI, and indicating a lack of 
coherence regarding explanations for MCI. Conversely, McIlvane, Popa, Robinson, 
Houseweart and Haley (2008) found a more mixed spectrum of emotional responses 
to MCI. Their cross-sectional study assessed a restricted range of illness beliefs about 
MCI, coping and quality of life (QoL). Their sample had generally low levels of 
distress and high QoL, reporting a range of positive emotional representations of MCI. 
Participants in their sample were already attending a support group, however, and 
tended to minimise the impact of their cognitive difficulties. Lingler et al. (2006) also 
noted mixed responses in their qualitative study, but identified meaning-making 
60 
 
themes from semi-structured interviews that were broadly consistent with the CSM, 
for example, appraisals regarding the consequences and understandability of MCI.     
  
Two studies have explicitly explored illness representations of MCI based on the CSM. 
Lin, Gleason and Heidrich (2012) adapted the Illness Perception Questionnaire-
Revised (IPQ-R) for use with MCI patients (IPQ-MCI) in an exploratory pilot study. 
Similar to McIlvane and colleagues (2008), levels of reported distress were low. In 
line with CSM predictions, participants endorsed more positive beliefs regarding 
chronicity, predictability, controllability and emotionality, though perceptions of 
consequences and coherence were more variable. Lin and Heidrich (2012) used the 
IPQ-MCI to evaluate the links between illness representations and coping style 
proposed by the CSM. They reported a similar pattern of beliefs, though MCI was 
viewed as more chronic in their sample, and identified associations between illness 
representations and the number of reported symptoms. People with few or moderate 
symptoms tended to have more positive beliefs while those with many symptoms 
tended to have more negative beliefs. These patterns were also associated with 
adaptive and maladaptive coping strategies, consistent with the CSM.  
 
The CSM offers a compelling framework for conceptualising psychosocial adjustment 
processes in MCI; however, findings regarding the significance of coping behaviours 
have been inconsistent in some populations with cognitive difficulties, such as 
Parkinson’s disease (PD; Kaptein et al., 2006) and subjective memory complaints 
(SMCs; Hurt, Burns & Barrowclough, 2011). Moreover, the model’s emphasis on 
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coping does not necessarily allow for the possible involvement of other psychological 
factors.  
 
Psychological Flexibility (PF) 
‘Psychological Flexibility’ is a central construct of Acceptance and Commitment 
Therapy (ACT), a psychological model forming part of the ‘Third Wave’ of cognitive 
behavioural therapies which is considered separately to the neuropsychological 
construct of cognitive flexibility, though there may be some conceptual overlap 
(Whiting, Deane, Ciarrochi, McLeod & Simpson, 2013).  PF is argued to promote 
flexible internal and external behavioural change through the linkage of present 
moment acceptance of unwanted private experiences (thoughts, feelings, memories, 
sensations) which may otherwise be avoided or suppressed, to the more adaptive 
pursuit of valued living (Hayes, 2004).  One of the main ways in which ACT differs 
from traditional cognitive behavioural therapy (CBT) is in its emphasis on how 
individuals relate to their negative thoughts rather than thought content. Indeed, one 
of the primary aims of ACT is not to reduce symptoms or negative affect per se, but to 
prevent them from acting as a barrier to valued living.  
 
ACT has been delivered successfully across a range of physical and mental health 
problems, for example, positive outcomes have been reported for mood and anxiety 
difficulties (e.g. Forman, Herbert, Moitra, Yeomans & Geller, 2007), chronic pain 
(McCracken, Vowles & Eccleston, 2005) and multiple sclerosis (MS; Sheppard, 
Forsyth, Hickling & Bianchi, 2010). Positive relationships have also been noted 
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between PF, QoL and psychological wellbeing (Hayes, Luoma, Bond, Masuda & 
Lillis, 2006) in these clinical populations, and with a community sample of older adults 
(Butler & Ciarocchi, 2007). Furthermore, Wetherell et al. (2011) reported 
improvements in mood and anxiety in their use of ACT with a population of older 
people. While ACT has not specifically been employed with an MCI population, 
Joosten-Weyn Banningh and colleagues (2011) developed a group intervention for 
MCI patients with the aim of increasing ‘acceptance’ of cognitive impairment, 
conceptualised as the integration of difficulties into the self-concept. They compared 
the intervention group with a wait-list control group, finding that acceptance increased 
in the former but not the latter. While overall distress and QoL ratings remained 
unchanged, increased acceptance was significantly correlated with reported wellbeing.    
 
Analysis of the links between change processes and outcomes in psychological therapy 
is common in ACT intervention studies. Despite some acknowledged variability in 
quality, numerous studies have consistently shown PF, along with specific ACT 
conceptualisations of ‘acceptance’ and ‘values’, to be significant mediators of change 
processes in both physical and mental health domains, at similar or superior levels to 
variables associated with other approaches, such as CBT (Hayes, Levin, Pulmb-
Vilardarga & Villatte, 2013). Few studies have investigated the possible influence of 
PF as a mediator of adaptive psychosocial adjustment to illness; however, work carried 
out by Ferenbach, Gillanders and Harper (2011) with an MS population reported that 
ACT constructs were stronger mediators of the relationships between MS symptoms, 
and psychological distress and life satisfaction outcomes than cognitive appraisals. A 
further study with MS patients also found evidence for the role of ACT constructs in 
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promoting positive adjustment outcomes (Pakenham & Fleming, 2011). Thus, there 
are some early indicators that PF may be a promising construct for further investigation 
of processes of change in psychosocial adjustment to MCI.    
 
Study aims 
The main objective of this exploratory study was to establish some preliminary 
evidence for the possible utility of ACT for MCI by evaluating the interrelationships 
between illness perceptions, cognitive impairment, PF, psychological wellbeing and 
QoL. It was hypothesised that: (1) more negative illness perceptions would be 
associated with poorer reported psychological wellbeing and QoL (2) higher levels of 
cognitive impairment would be associated with poorer reported psychological 
wellbeing and QoL (3) illness appraisals would be more strongly associated with 
outcome variables than cognitive impairment and (4) lower levels of PF would be 
associated with more negative illness perceptions, greater severity of cognitive 




This quantitative study used a cross-sectional, questionnaire-based design to analyse 
the relationships between cognitive impairment, illness representations, PF, 
psychological wellbeing and QoL. Ethical approval was granted by the NHS South 





Nineteen patients were recruited from local NHS memory clinic services with a 
diagnosis of MCI according to ICD-10 criteria (WHO, 1992) supported by clinical 
history, physical examination, cognitive testing (Addenbrookes’ Cognitive 
Examination-III, ACE-III; Hsieh, Schubert, Hoon, Mioshi & Hodges, 2013) and where 
deemed necessary, neuroimaging. During the period of March 2014 to August 2014, 
participants were either referred by memory service clinicians (Consultant 
Psychiatrists, Community Psychiatric Nurses, Clinical Psychologists) via assessment 
or follow-up appointments, or were identified following a case-file review of service 
attendees by the lead author (AS). Nine participants meeting criteria were referred by 
clinicians following clinic attendance, while 13 participants out of 60 who were invited 
by post following case-file review chose to opt in to the study, representing a response 
rate of 21.6%. Two of the participants referred by clinicians subsequently declined to 
take part and one was judged unable to provide informed consent.  
 
Participants were required to be over the age of 60, fluent in English and diagnosed 
with MCI within the past 9 months in order to be eligible. This timeframe was limited 
in order to minimise the likelihood of further cognitive decline. Exclusion criteria 
comprised: pre-morbid cognitive difficulties; prior head trauma; history of substance 
misuse; current residential care placement; current psychiatric diagnosis; current 
significant physical illness. These criteria were chosen in order to eliminate potential 
confounding factors for subjective QoL ratings. Sample characteristics are 




During case-file review, a further 23 patients with MCI were identified who did not 
meet inclusion criteria for the following reasons: significant physical health 
comorbidity (n=8); diagnosis of MCI > 9 months (n=7); current or past history of 
substance misuse (n=3); current residential care placement (n=2); previous head 
trauma (n=2); significant sensory impairment (n=1). 
 
Measures 
Participants completed self-report measures independently; all other measures 
(MoCA, IPQ-MCI) were administered by the lead author (AS). The following 
measures were completed: 
 
Montreal Cognitive Assessment (MoCA). The MoCA (Nasreddine et al., 2005) is a 
brief cognitive screening tool which purports to measure various cognitive domains, 
including memory, visuospatial ability, language and executive functioning. The 
MoCA is scored out of 30, and a clinical cut-off of 26 and above is considered to be 
within the non-clinical range. An additional point is added for patients with 12 years 
of education or less. The MoCA was developed as an alternative to the Mini-Mental 
State Examination (MMSE; Folstein, Folstein & McHugh, 1975), reported to have 
limited efficacy for MCI (Mitchell, 2009). MoCA validation studies have consistently 
shown high levels of sensitivity for MCI, though specificity is more variable (for a 
discussion of these issues, see the current systematic review).  
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Geriatric Anxiety Inventory – Short Form (GAI-SF). The GAI-SF (Byrne & 
Pachana, 2011), adapted from the original Geriatric Anxiety Inventory (GAI; Pachana 
et al., 2007), comprises 5 items which participants either endorse or reject 
(agree/disagree). While the psychometrics of the longer GAI are more robust (Byrne 
& Pachana, 2011), it is still considered to be a psychometrically adequate scale and its 
brevity of administration made it a more suitable tool for the current study in order to 
minimise fatigue. Scoring 3 or more is considered clinically significant, with fair 
sensitivity and good specificity (Byrne & Pachana, 2011). While the GAI-SF has not 
been validated for use by people with MCI, it has been successfully administered to a 
population of memory clinic attendees (Byrne, Pachana, Arnold, Appadurai & Chalk, 
2008).  Cronbach’s α for the scale in the current population was .72. 
 
Geriatric Depression Scale-5 (GDS-5). The GDS-5 (Hoyl et al., 1999) is a shortened 
version of the original 30-item scale developed by Yesavage and colleagues (1983) 
with high levels of sensitivity and specificity. Respondents either endorse or reject 
(yes/no) each item and the scale has a clinical cut-off of 2 or more. The GDS-5 has 
previously been administered successfully to patients with MCI (Lin et al., 2012). 
Cronbach’s α for the current population was .10. 
 
Acceptance and Action Questionnaire-II (AAQ-II). The AAQ-II (Bond et al., 2011) 
is a 7-item measure of psychological inflexibility. Individual differences in PF are 
assessed via 7 statements, which participants rate using a 7-point Likert scale (never 
true to always true), with higher scores indicating lower levels of PF. The AAQ-II has 
67 
 
not previously been validated with an MCI population; however, it has been used 
successfully with an MS population (Ferenbach et al., 2011; Gillanders & Gillanders, 
in press). Cronbach’s α for the scale in the current population was .74. 
 
Illness Perception Questionnaire – Mild Cognitive Impairment (IPQ-MCI) 
The IPQ-MCI was adapted from the IPQ-R (Moss-Morris et al., 2002), a broad 
measure of illness appraisals developed for applicability across a range of health 
problems. The IPQ-MCI has been piloted and validated for use with people with MCI 
(Lin et al., 2012) and comprises 9 subscales: identity (27 items); causes (25 items); 
consequences (12 items); chronic timeline (5 items); cyclic timeline (4 items); personal 
control (6 items); treatment control (5 items); coherence (5 items) and emotional 
representation (8 items). Items in the identity subscale are rated dichotomously 
(Yes/No) and are made up of a various cognitive and somatic symptoms which 
participants categorise as being related or unrelated to MCI. Participants also record 
the number of symptoms they currently experience. These are interpreted qualitatively 
in relation to whether participants tend to experience cognitive symptoms, such as 
forgetfulness, or somatic symptoms, such as headaches. Items in the remaining 
subscales are endorsed or rejected according to a 5-item Likert scale (strongly disagree 
to strongly agree). Higher scores indicate greater strength of negative illness beliefs. 
The cause subscale is interpreted qualitatively. Values of Cronbach’s α for IPQ-MCI 
subscales in the current study are as follows: chronicity (.85), consequences (.77), 
personal control (.86), treatment control (.83), coherence (.81), cyclic (.62), emotional 
representations (.79)..   
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Quality of Life in Alzheimer’s Disease (QOL-AD). The QOL-AD (Logsdon, 
Gibbons, McCurry & Teri, 2002) is a self-report tool providing a subjective measure 
of QoL from the individual’s perspective. It is commonly used in dementia research 
and the authors report good reliability and validity with this population. The scale 
comprises 13-items spanning various aspects of QoL which respondents rate on a 4-
point Likert scale (poor to excellent). Higher scores indicate higher perceived QoL. 
Cronbach’s α for the QOL-AD in the current study was .83. 
 
Procedure 
Participants met with an appropriately trained researcher experienced in working with 
this population (AS) to complete the 6 measures, along with a general questionnaire 
collecting demographic information, at a hospital clinic setting or in their own homes. 
Each participant provided written informed consent prior to commencing the 
assessment appointment. All measures were administered in the same order (MoCA, 
GAI-SF, GDS-5, AAQ-II, IPQ-MCI, QOL-AD) in a single session lasting 
approximately 60 minutes, apart from one participant who required 2 sessions after 
experiencing distress completing the IPQ-MCI. 
 
Data analysis 
Analysis was conducted using SPSS 21. Descriptive statistics were computed for each 
study variable and are presented in Table 2. All participants who consented to take part 
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completed full data sets. No missing data was recorded. In order to address the research 
objectives, bivariate correlations were computed to test the associations between the 
following: illness representation variables (IPQ-MCI) and adjustment variables (GAI-
SF, GDS-5, QOL-AD); cognitive impairment (MoCA) and adjustment variables (GAI-
SF, GDS-5, QOL-AD); and PF (AAQ-II) and all other variables. 
 
In order to meet the assumptions for correlational analysis, data for all interval 
variables was tested for normality using the Shapiro-Wilk test at p>0.05 based on 
recommendations by Field (2009) for small sample sizes. Four study variables and one 
demographic variable were found to violate parameters for normality: GAI-SF 
(p=0.02); GDS-5 (p<0.001); treatment control (p=0.01); emotional representation 
(p=0.01); retirement age (p<0.001). When z-score values of skewness and kurtosis 
were calculated for these values, the GAI-SF, GDS-5 and emotional representation 
variables were found to be within normal parameters of +/- 1.96 (Field, 2009). The 
treatment control variable was negatively skewed, however, while the retirement age 
variable was also negatively skewed and had high kurtosis. Square root, ‘log10’ and 
‘reciprocal’ transformations were computed for these two variables but did not result 
in a normal distribution. Spearman’s ρ correlations were therefore computed for these 









The mean age of the sample was 78 with the average retirement age being 61, though 
one participant remained in employment. The sample was skewed towards male 
participants and was well educated. The mean MoCA score was in line with normative 
data for MCI gathered from similar populations (e.g. Nasreddine et al., 2005). The 
majority of participants took part within 6 months of receiving an MCI diagnosis, 
though a considerable proportion of the group reported experiencing cognitive 
difficulties for more than 3 years prior to diagnosis.  
 
Correlations between demographic characteristics and study variables were calculated 
in order to assess the potential for confounding factors. No significant correlations 
were found in relation to age, education, retirement status or number of months since 
diagnosis. Older age at retirement was, however, found to be associated with more 
negative beliefs regarding the consequences of MCI (ρ=.53, p=.02; p<0.05) and 














Participants tended to score more highly on the GAI-SF than the GDS-5, indicating 
that anxiety was more prevalent within the study population than difficulties with 
Characteristic (n=19) Mean (SD) 
Age, years  77.63 (4.89) 
Education, years 14.16 (5.09) 
MoCA score 22.21 (2.12) 
Time since diagnosis, months 5.07 (2.59) 
Age at retirement, years (n=18) 60.83 (5.48) 
 Frequency (%) 
Males   12 (63.16) 





















depressed mood. Scores on the AAQ-II are indicative of relatively high levels of PF, 
though the distribution of scores on this measure indicates some variability. The 
average number of symptoms reported by participants was 8, while the average  
 
Table 2 Descriptive statistics for study variables  





Variable Mean (SD) Mean (SD) N 
MoCA 22.21 (2.12) 22.20 (3.34)b 63 
GAI-SF 1.79 (1.65) 1.1 (2.3)d 22 
GDS-5 0.84 (0.83) 1.57 (1.41)c 30 
AAQ-II 12.63 (5.42) 18.95 (11.30)f 133 
Identity 13.37 (5.45) 7.00 (4.25)b 63 
Chronicitya 3.59 (0.77) 3.82 (0.72)b 63 
Consequencesa 2.69 (0.64) 3.21 (0.69) b 63 
Personal controla 2.59 (0.88) 2.57 (0.65) b 63 
Treatment controla 2.6 (0.71) 2.74 (0.63) b 63 
Coherence 2.95 (0.71) 2.80 (0.87) b 63 
Cyclica 2.57 (0.32) 2.75 (0.72) b 63 
Emotional 
representationa 
2.97 (0.65) 2.75 (0.66) b 63 
QOL-AD 40.63 (6.18) 39.2 (4.7)e 47 
 
Note: SD= standard deviation. aMean item score; bFrom Lin et al. (2012) MCI sample; cFrom Lin et 
al. (2011)MCI sample; dFrom Byrne & Pachana (2011) older adult sample; eFrom Logsdon et al. 
(2002) dementia sample; fFrom Ferenbach et al. (2011) MS sample. 
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number of symptoms attributed to MCI was 13.47, suggesting that MCI may have been 
viewed as more severe than what was currently experienced. The most commonly 
reported symptoms were cognitive and related mainly to memory difficulties. Some 
somatic symptoms were noted, but these tended to be less associated with MCI than 
cognitive symptoms. The most frequently endorsed causes of MCI were: stress, 
heredity, age and abnormal changes in the brain. 
 
Mean item scores were calculated for the remaining subscales of the IPQ-MCI, with 
higher scores corresponding with strength of negative beliefs. MCI was perceived to 
have a more chronic timeline and was associated with emotional distress and limited 
perceived understanding of MCI. Overall, however, participants tended to report 
feeling in control of their condition and believed that MCI could be managed by 
treatment. The mean QOL-AD score suggests that, in general, participants’ perceived 
QoL was high, though the spread of scores was somewhat variable. Participants tended 
not to notice cyclic changes in their experience of symptoms and did not perceive the 
consequences of MCI to be significant. 
 
Correlational analysis 
Correlation coefficients for study variables are summarised in Table 3. 
Illness representations. The relationships between illness representation subscales of 
the IPQ-MCI were analysed. Perception of more severe chronicity was associated with 
a lower sense of personal control over MCI symptoms (p=.01; p<0.01), with higher 
levels of emotional distress (p=.05; p<0.05) and with less perceived treatment 
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effectiveness (p=.03; p<0.05). Decreased personal control was also associated with 
decreased belief in treatment (p<0.001). When MCI consequences were perceived as 
more serious, this was associated with a perception of greater symptom 
unpredictability (p<0.001) and greater emotional distress (p<0.001). 
 
Illness representations, psychological wellbeing and QoL. Higher anxiety as 
measured by the GAI-SF was significantly associated with more serious perceived 
consequences (p=.04; p<0.05) and with more negative emotional representations of 
MCI (p<0.001), but there were no other significant correlations between the GAI-SF 
and IPQ-MCI subscales. Mood difficulties and QoL were not found to be associated 
with any category of illness representations; however, there was a relationship between 
increased mood difficulties and lower perceived QoL (p=.01; p<0.05). 
 
Cognitive impairment, psychological wellbeing and QoL. No correlations were 
found between the MoCA, mood, anxiety or QoL. When the number of self-reported 
symptoms was considered, however, participants experiencing greater 
symptomatology perceived their QoL as lower (p=.01; p<0.05). 
 
The role of PF. The relationships between PF, cognitive impairment, illness 
representations, psychological wellbeing and QoL were computed. Lower PF was 
associated with poorer QoL (p=.01; p<0.05). Low PF was also correlated with low 




Table 3 Correlations among study variables 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11.a 12. 13. 14. 
1. MoCA 1 .12 .37 .52* -.34 .44 -.36 .31 .06 .13 .08 .24 -.18 .13 
2. GAI-SF  1 .22 .32 -.09 -.24 .00 .42 .48* -.02 .14 .24 .00 .62** 
3. GDS-5   1 .59** -.57* .10 -.01 .44 -.03 .27 .35 .15 -.02 .32 
4. AAQ-II    1 -.55* .40 -.28 .11 .07 -.07 .04 .39 .04 .32 
5. QOLAD     1 -.51* -.20 -.14 .02 -.29 -.25 -.17 -.03 -.07 
6. Symptoms      1 .09 .12 -.05 .39 .25 .02 -.21 -.12 
7. Identity       1 .13 .22 .23 .20 -.24 .20 .30 
8. Chronicity        1 .37 .61** .51* .20 -.29 .46* 
9. Consequences         1 .30 .35 .65** -.04 .64** 
10. Personal 
control 
         1 .73** .22 -.29 .29 
11. Treatment 
controla 
          1 .32 .00 .18 
12. Cyclic            1 -.14 .33 
13. Coherence             1 .19 
14. Emotional 
representations 
             1 





Illness representations and adjustment to MCI 
The results of the current study added to the evidence base for the CSM in psychosocial 
adjustment to MCI, finding partial support for hypothesised parallel processes. Belief 
in more negative consequences was significantly associated with increased anxiety. 
Previous quantitative studies of illness perceptions with MCI populations have not 
specifically assessed anxiety, however, a comparatively more anxious PD population 
also showed a significant relationship with negative consequences (Evans & Norman, 
2009). In the current study, negative emotional representations were also associated 
with elevated anxiety, similar to relationships observed in other populations with 
cognitive difficulties, including PD (Evans & Norman, 2009) and SMCs (Hurt et al., 
2011). Given the small sample size in the current study and use of correlational 
analysis, however, neither causality nor directionality of these relationships can be 
definitively concluded. 
 
The uncertainty surrounding a diagnosis of MCI is likely to give rise to a spectrum of 
emotional representations and beliefs regarding consequences, especially since people 
with MCI may improve, remain stable or experience cognitive decline in the future. 
The nature of cognitive difficulties, in association with the increased risk of developing 
dementia could be involved in the development or exacerbation of anxiety in people 
with MCI (Frank et al., 2006; Joosten-Weyn Banningh & Vernooij-Dassen, 2008; 
Lingler et al., 2006), but this relationship is also likely to be reciprocal (Baudreau & 
O’Hara, 2008). Furthermore, positive emotional representations of MCI have been 
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reported where overall levels of distress are low (McIlvane et al., 2008). The way in 
which the potential outcomes of MCI are conveyed to patients may influence beliefs 
regarding consequences and the level of distress patients associate with this, and thus 
may subsequently affect adaptive psychosocial adjustment. Negative beliefs about the 
consequences of MCI, such as ‘MCI will progress to dementia’, and cognitions 
associated with negative emotional representations, such as ‘My MCI makes me feel 
uncertain about the future’ may therefore represent potentially useful therapeutic 
targets for patients who have adjustment difficulties. 
 
No other domains of illness belief were found to be related to psychological wellbeing 
or QoL, in contrast to the results of previous studies using populations with cognitive 
problems (Evans & Norman, 2009; Ferenbach et al., 2011; Hurt et al., 2011; Jopson & 
Moss-Morris, 2003; Lin et al., 2012).  One possible explanation is that the overall 
heterogeneity of MCI aetiology may have resulted in differences in individual 
experiences of MCI. Indeed, differences in coping, understanding and emotional 
responses to MCI are well documented (Dean & Wilcock, 2012; Joosten-Weyn 
Banningh & Vernooij-Dassen 2008; Joosten-Weyn Banningh et al., 2011; Lingler et 
al., 2006). Additionally, participants in the present study tended to score low on the 
GDS-5 and high on the QOL-AD, which was reflected in the significant correlation 
obtained between these two variables. This suggests that the current sample may 
represent a relatively well-adjusted group. Recruitment of patients with late-life 
depression into research studies has historically been associated with challenges 
(Thompson, Heller & Rody, 1994), and it is possible that patients with low mood were 
more likely to choose not to opt in to the current study. In addition, the internal 
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consistency of the GDS-5 with this population was low, which has implications for the 
overall validity of this scale as a measure of mood in the current study. 
 
The hypothesised associations between illness representations and adjustment 
variables may also be more likely to emerge where severity of mood and anxiety 
difficulties is elevated. Indeed, Lin and Heidrich’s (2012) sample scored more highly 
on the GDS-5 and reported an association between mood and perceived severity of 
illness identity. Furthermore, the current sample scored low overall on the GAI-SF, 
though significant associations with some illness representations were noted. It is 
possible, therefore, that replicating these findings with a more anxious population may 
yield further associations with domains of illness belief.  
 
Findings of complex interrelationships between specific illness representations in the 
current study would intuitively suggest that these may be important for psychosocial 
adjustment, though only limited direct evidence was established. On a descriptive 
level, these interrelationships offer insight into additional potential drivers for 
therapeutic change for people with MCI. Appraisal of more serious consequences was 
associated with less perceived symptom controllability and more negative emotional 
representations, which was also related to the perception of greater chronicity. 
Heightened belief in incurability was also associated with decreased personal control 
and belief in treatment effectiveness. These relationships have been consistently 
reported in similar populations (Evans & Norman, 2009; Hurt, Burns, Brown & 
Barrowclough, 2010; Lin & Heidrich, 2012). There are currently no accepted or 
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prescribed interventions for MCI, and patients may have limited knowledge about 
what could be done to improve or alleviate the course of their illness. Perceptions of 
helplessness have been associated with emotional distress in previous studies with 
cognitively impaired individuals, including MS (Ferenbach et al., 2011), and may also 
interfere with psychosocial adjustment. 
 
Cognitive impairment and adjustment to MCI 
Objective measurement of cognitive impairment using the MoCA was not associated 
with illness representations or outcome variables. While assimilation of concrete 
illness information is an integral component of the CSM, some studies have not found 
robust links between illness severity and psychosocial adjustment (e.g. Jopson & 
Moss-Morris, 2003), though this is not a consistent finding (Ferenbach et al., 2011; 
Schiaffino, Shawaryn & Blum, 1998). Given the inherent difficulties of quantifying 
cognitive impairment using screening measures, it is possible that use of the MoCA 
did not provide an accurate estimate of participants’ functioning. While the MoCA has 
consistently been found to have high levels of sensitivity with this population, 
specificity is variable. In addition, the average educational level of the current sample 
was relatively high, which may have inflated cognitive scores. Nevertheless, each 
participant’s classification status was supported by clinical investigation and the mean 





An alternative explanation may relate to the aforementioned heterogeneity of MCI. 
The aetiology of this classification is commonly attributed to the onset of an early 
neurodegenerative process; however, cognitive impairment can result from both 
physical and mental health difficulties which are not necessarily neurodegenerative 
(Petersen, 2004), and which may result in different qualitative experiences for patients. 
Indeed, in the current study, though objective impairment was not associated with 
psychosocial adjustment, higher number of reported symptoms was significantly 
correlated with poorer QoL. This is similar to the pattern noted by Lin and Heidrich 
(2012). Symptoms may be both cognitive and somatic in nature. The latter may include 
underlying anxiety or physical health problems which impacted on perceived QoL; 
however, participants with significant physical illness were not contacted for 
participation in the current study and the overall level of anxiety was low. Thus, within 
the context of the CSM, lived experience of MCI may be more important in 
understanding the impact of MCI than measured cognitive impairment.  
 
Illness representations or cognitive impairment? 
A further aim of the current study was to assess the comparative strengths of the 
relationships between negative illness representations, increased cognitive impairment 
and poorer adjustment outcomes. The only significant correlations in line with these 
posited relationships were between consequences and anxiety, emotional 
representations and anxiety, and between number of reported symptoms and QoL. All 
correlation coefficients were of similar magnitude; however, reported experiences of 
MCI symptomatology could be argued to have a greater emphasis on internal 
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representations of illness compared with objective cognitive measures. Clinical 
decisions regarding management, along with judgement of the likely effects of MCI, 
and how this is communicated to patients may be more reliant on cognitive evidence. 
The results of the current study therefore support findings from qualitative studies that 
consideration of individual experiences may be more crucial in understanding the 
implications of MCI for patients than considering the degree of cognitive impairment.    
       
The role of PF 
A further aim of the current study was to assess the potential associations between 
psychological inflexibility, negative illness representations, greater severity of 
cognitive impairment and poorer adjustment outcomes. The results of the correlational 
analysis provide some preliminary, tentative evidence for the possible involvement of 
PF in psychosocial adjustment processes. Psychological inflexibility was associated 
with low mood and low perceived QoL, both of which may be indicative of 
maladaptive psychosocial adjustment;however, the low internal consistency of the 
GDS-5 in the current population is likely to have affected the validity of these findings. 
These relationships have been reported by a number of studies with various physical 
and mental health populations (for a meta-analysis see Hayes et al., 2006), and work 
by Butler and Ciarocchi (2007) found that high PF was predictive of higher perceived 
QoL in a community sample of older adults. As conceptualised in ACT, the 
mechanism by which increased PF is proposed to influence change is not through the 
reduction of psychological distress per se, but in the facilitation of valued living, which 
may in turn lead to the reduction of distress (Hayes, 2004). Thus, while interpretation 
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of the associations between PF, mood and QoL is constrained by statistical and sample 
size limitations, the current study offers a plausible rationale for further investigation 
of these potential interrelationships.   
 
Interestingly, psychological inflexibility was also associated with less cognitive 
impairment, contrary to previous findings with an MS population (Pakenham & 
Fleming, 2011). There may be an overlap between PF and cognitive flexibility, an 
ability associated with executive functioning which includes the capacity to switch or 
‘shift’ between different concepts. Whiting et al. (2013) investigated the relationship 
between PF and cognitive flexibility in a population of people with acquired brain 
injuries, finding associations between PF and some components of cognitive 
flexibility, such as verbal flexibility, but noting no overall association with cognitive 
‘shifting.’ A decrease in cognitive flexibility would typically be expected as cognitive 
impairment increases. Thus, PF might also be expected to decrease. The finding of an 
association between lower PF and lower cognitive impairment in the current study is 
therefore unexpected. One possible explanation for this may relate to sample size, or 
to the high levels of PF in the study population.  
 
Insight into cognitive difficulties may also be implicated. Depression has consistently 
been associated with greater insight into cognitive difficulties in people with dementia 
(Horning, Melrose & Sultzer, 2014), and the current study reported an association 
between low PF and low mood. The relatively low level of cognitive difficulty in MCI 
would suggest that poor insight is less likely, though this has been found to vary in 
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MCI populations (Roberts, Clare & Woods, 2009). The current study did not assess 
self-awareness of cognitive difficulty, but this may be an important consideration for 
future research in this area. 
 
Limitations of the current study 
The current study was limited by small sample size and a high number of multiple 
comparisons with insufficient statistical power largely driven by significant 
recruitment difficulties. Low recruitment numbers may reflect the stringent inclusion 
and exclusion criteria applied in the current study; however, these criteria were 
designed to minimise potential confounding factors. The response rate for patients 
contacted by post was low (21.6%). Knechel (2013) argues that various factors can 
impede older adults’ participation in research studies, including use of lengthy 
documents, and difficulty accessing research sites. The authors attempted to minimise 
the complexity of information sent to participants and offered home visits for those 
unable to attend NHS sites; however, it is possible that these factors reduced uptake of 
postal invitations. 
 
Few UK MCI epidemiological studies have been conducted; however, a 2008 study 
by Fish and colleagues (cited in Ward, Arrighi, Michels & Cederbaum, 2012) reported 
a prevalence of 15.6% in a sample of male older adults, though these rates are likely 
to be affected by MCI heterogeneity and varying diagnostic practices. It is also 
possible that some MCI patients were not identified by their general practitioners 
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(GPs) as requiring further memory assessment. A recent study by Kaduszkiewicz et 
al. (2010) suggested that the sensitivity of GP judgement of MCI was only 11-12%. 
 
The majority of participants in the current study were male and the overall education 
level of the sample was relatively high. Therefore, the pattern of results obtained may 
not be representative of the wider population of MCI patients. The high number of 
male participants who opted in to the study was unexpected. Men may be more likely 
to use problem-focussed coping strategies compared to women (Baker & Berenbaum, 
2007), and they may have viewed research participation as a possible strategy; 
however, males may be less likely to use coping strategies overall in the management 
of health problems (e.g. Englbrecht et al., 2012). The current study did not assess 
coping style, which may have allowed further exploration of this issue and of the role 
of coping in adjustment to MCI. Evidence for the significance of coping style on 
psychosocial adjustment to cognitive difficulties is equivocal, however, with both 
supportive (Lin & Heidrich, 2012) and contradictory (Hurt et al., 2011) findings 
identified. It was also considered that including a measure of coping would increase 
the potential for fatigue in older adult participants with cognitive impairment.    
 
The current study employed correlational analysis to explore the relationships between 
independent and dependent variables. The limitations for the use of correlations in 
cross-sectional studies to indicate causation are well known, thus, these results must 
be interpreted cautiously. In addition, correlation coefficients obtained from small 
samples tend to be more variable (Field, 2009), this means that the relationships 
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observed in the current study may have limited validity, and may also be susceptible 
to both type-I and type-II errors, particularly since high numbers of comparisons have 
been computed. These significant caveats restrict the conclusions which can be drawn 
from the current results. Replication of these findings with a larger sample, however, 
would have a number of important theoretical and clinical implications. 
 
It is noteworthy that the IPQ-MCI subscales tended to correlate with each other more 
than with outcome variables. The exceptions to this are the relationships between 
consequences and anxiety, and emotional representations and anxiety, both of which 
are likely have a reciprocal component. Emotional representations and anxiety also 
have a considerable conceptual overlap, and though the size of the correlation 
coefficient was not indicative of collinearity in this small sample, a larger population 
may show this. Interestingly, in comparison to specific illness representations, the 
correlation coefficients in the relationships between PF and adjustment variables were 
larger. In line with this, the clinical and theoretical underpinnings of ACT would 
emphasise PF rather than appraisal content as being the main vehicle for therapeutic 
change. Thus, promoting PF may represent a promising direction for future research 
and may convey some therapeutic benefit; however, these results must be considered 
within the context of a high number of comparisons across a small population, with 
most comparisons resulting in non-significant relationships and small effect sizes. The 
limited number of significant relationships between specific illness beliefs and 
outcome variables may therefore reflect low statistical power. For example, the 
correlation coefficients denoting the relationships between chronicity and distress 




Clinically, considered within the context of the aforementioned statistical limitations 
these results would be consistent with previous findings that individuals’ 
interpretations and experiences of MCI are likely to affect their adjustment to the 
condition. This could have implications for both how an MCI classification is 
delivered and explained, and how it is subsequently followed up. Increased awareness 
of these factors for clinicians and carers is therefore likely to be beneficial, and the 
current findings also suggest that offering psychosocial support to people with MCI 
following diagnosis in order to explore illness perceptions, particularly where there 
may be indications of adjustment difficulty, may be of therapeutic value. Thus, the 
possible viability of psychological interventions aimed at targeting thought content or 





The current study provided some limited further support for the relevance of illness 
representations in psychosocial adjustment to MCI and added to the evidence base by 
also exploring the relationships between PF, distress and QoL in people with MCI. 
Both emotional representations of MCI and beliefs about the consequences of this 
condition were associated with anxiety in this population, and further exploration of 
this potential relationship with a larger sample may provide a more robust link. In 
addition, the current study found some limited evidence to suggest that individual 
experiences of MCI symptoms may be more relevant to the adjustment process than 
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objective cognitive impairment, though this was not a hypothesised finding. Finally, 
some early support was found for the potential involvement of PF in psychosocial 
adjustment. People who are able to take a more flexible stance in the presence of 
distress or other unwanted internal experiences, may be more likely to report positive 
wellbeing and QoL. Further research with a larger and more representative sample is 
needed to assess the robustness of these associations and to establish whether PF may 
be a mediator of change in this context, and hence whether ACT may convey some 
benefit to people who experience difficulty adjusting to MCI. Nevertheless, the current 
study has added to evidence that both cognitive content and acceptance factors may 
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Appendix A1 Systematic Review Assessment Checklist Operational Criteria 
for scoring  
 
1. Abstract identifies the article as a diagnostic accuracy study, and clearly reports 
study methodology, results and conclusions 
 
Yes: Abstract uses term 'diagnostic accuracy', 'sensitivity and specificity', 'validation study' or 
equivalent. Methodology should cover setting (clinical versus population-based), groups and 
numbers of participants, and index tests used (with translated versions if applicable). The 
abstract clearly identifies the condition(s) being assessed. Results should contain the main 
outcomes of diagnostic statistical tests carried out (including AUC, sensitivity, specificity, 
PPV, NPV, optimal cut-off). Overall conclusions should be related to results reported and to 
overall accuracy/validity of MoCA. 
 
No/Unclear: Study does not meet above criteria or reports results of diagnostic tests without 
clear use of terms 'diagnostic accuracy', 'sensitivity and specificity' or equivalent. 
 
2. Introduction clearly outlines the research question(s) and/or study aim(s) 
 
Yes: There is a clear delineation of aims consistent with the content of the introduction and 
states these as either a set of questions or objectives which are clearly operationalised. Aims 
and objectives are stated in a way that allows the reader to judge the applicability of setting, 
inclusion/exclusion criteria, procedure and analysis. 
 
No/Unclear: The aims of the study are either not stated, are inconsistent with introduction 
content OR are general/vague and do not allow the reader to judge the applicability of 
setting, inclusion/exclusion criteria, procedure and analysis.  
 
3. The methods of recruitment of the study population are described and appropriate1 
 
Yes: Information is presented in sufficient detail to permit replication. Each stage of the 
recruitment process for each group (if more than one) should be present and it should be 
clear how participants were identified. 1Participants should be identified based on presenting 
symptoms from consecutive referrals to the memory/dementia/geriatric clinic where 
MCI/dementia is suspected, or from a random sample of these. 
 
No: Information is either absent OR bias may be present in how participants were recruited 
(i.e. study may be retrospective, based on data collected or performance on index test and 
reference standard, or different recruitment methods may have been used to recruit each 
group).  
 
Unclear: Insufficient information is presented for the reader to be able to make a judgement.   
 
 
4. The study population is representative of the patients who would typically receive the 
test in practice  
 
Yes: The sample population would be expected to receive the test as a result of attending a 
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memory clinic, geriatric inpatient or outpatient setting. Studies should score 'yes' if they do 
not use case-control methodology (i.e. comparison of participants confirmed to have the 
condition of interest with participants confirmed not to have the condition of interest), if they 
are judged to not have unnecessarily excluded groups of participants who might be expected 
to receive the test in practice (i.e. if the population is not restricted to, for example, specific 
MCI subtypes or particular physical health problems, such as cerebrovascular disease), and if 
the locations and settings are in line with stated aims (e.g. memory clinic, rural/urban 
setting).    
 
No: Study clearly does not meet above criteria: case-control methodology is used, bias is 
present in inclusion/exclusion criteria or locations/settings do not correspond with stated 
aims. 
 
Unclear: Insufficient information is reported to enable the reader to make a judgement.    
 
5. The reference standard and its execution are appropriate (i.e. likely to correctly 
classify the target condition) 
 
Yes: The reference standard for MCI should be based on criteria outlined by Petersen and 
colleagues, which may be supplemented by other recognised valid clinical tools/standards 
for MCI (e.g. ICD-10), and is supported by clinical diagnosis on the basis of the following: 
clinical history, physical/neurological examination, neuroimaging, neuropsychological 
assessment. 
 
Reference standard for dementia (if applicable) involves clinical diagnosis as above and is 
based on reliable and valid clinical criteria (i.e. DSM-IV, ICD-10, NINCDS-ADRDA, CDR). 
 
Reference standard for NCI involves clinical diagnosis as above and is based on 'normal' 
criteria using the same diagnostic standards for MCI and dementia. 
 
No: Study does not meet criteria outlined above. Bias is present in the choice of reference 
standard (i.e. an unvalidated test or one which has reduced validity in classifying the 
condition of interest). 
 
Unclear: Insufficient information is available for the reader to be able to judge the 
appropriateness of the reference standard. 
 
6. The number and expertise of the persons executing and interpreting the reference 
standard would be considered appropriate2 
 
Yes: The number of people is clearly stated, including position/level of training/experience.   
2Appropriate: consensus panel with a range of experience across categories of information 
gathered (i.e. psychiatrist, geriatrician, neuropsychologist, neurologist) 
 
No: Information is absent OR bias is present in number/expertise (i.e. decisions made by 
persons who would be judged to have insufficient knowledge/experience, or by the 
judgement of a single person) 
 
Unclear: Information is not presented with sufficient detail for the reader to be able to judge 
expertise/qualification to make diagnostic decisions  
 




Yes: The appropriate language version of the test is used (i.e. the language of the test reflects 
the linguistic and cultural background of participants). If a translated version is used, 
translation should include back-translation, consensus decision-making, independent 
verification and pilot testing. Where other tests are employed (e.g. MMSE) these may 
influence interpretation of the MoCA and should therefore be carried out subsequently.  
 
No: Bias may be present in the translation process (e.g. lack of independent translators or 
pilot testing), OR in the interval/timing of the index test (e.g. interval of longer than 6 
months or index test is carried out after another diagnostic test such as the MMSE). 
 
Unclear: Insufficient information is available for the reader to be able to judge 
 
 
8. The number and expertise of the persons executing and interpreting the index test 
would be considered appropriate3 
 
Yes: The number of people is clearly stated, including position/level of training/experience. 
3Appropriate: The person(s) administering the MoCA should have training in 
neuropsychological assessment. If more than one person, level of agreement should be 
calculated. If additional neuropsychological tests are being co-administered by the same 
rater, the MoCA should be administered first. 
 
No: Information is absent OR bias is present in number or level of training/expertise (i.e. 
conducted by a person who would be considered to have insufficient training; OR two or 
more raters with no consideration of interrater agreement; OR if one rater administers all 
tests and there is an indication that this may introduce bias due to order of test 
administration) 
 
Unclear: Information is not presented with sufficient detail for the reader to be able to judge 
expertise/level of training, or number of test administrators.  
 
9. All participants receive the same reference standard 
 
Yes: It is clearly stated that all participants, regardless of initial diagnosis (if this is applied), 
have their status confirmed using the same reference standard. 
 
No: Only participants with clinical diagnoses receive the reference standard OR only a 
random sample receive the reference standard 
 
Unclear: Insufficient information is presented to allow the reader to make a judgement as to 
whether all participants receive same reference standard. 
 
10. The index test results were interpreted without knowledge of the reference standard 
results 
 
Yes: The index test is clearly carried out prior to diagnostic confirmation OR it is stated that 
the individuals administering the index test are independent  or 'blinded' to reference 
standard results 
 
No: Index test carried out after reference standard and it is stated that person(s) 
administering index test are not 'blinded' to diagnosis, OR performance on reference standard 
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may form part of inclusion criteria OR additional clinical information may be available to 
the person(s) administering the index test. 
 
Unclear: Insufficient information is presented so as to allow the reader to make a judgement. 
 
11. The reference standard results were interpreted without knowledge of the index test 
results 
 
Yes: Clearly stated that diagnostic decision-making is made without reference to the index 
test AND/OR diagnostic decision-makers were independent of index test raters, OR it is 
clear that index test results could not have been involved in interpretation of diagnostic status 
if this is carried out prior to index test 
 
No: Clear that index test results informed the reference standard, OR even if stated that index 
test results do not inform the reference standard, it may be clear that index test raters are 
involved in diagnostic decision-making. 
 
Unclear: Insufficient information is presented to enable the reader to make a judgement. 
 
12. Index test results were interpreted according to a pre-determined cut-off 
 
Yes: All versions of the test should be interpreted according to a pre-determined cut-off, 
whether this is the original cut-off for the English version, or whether sufficient justification 
is provided for another cut-off (e.g. translated versions with similar cultural/linguistic 
variations, or similar ethnic/cultural variation). 
 
No: Only an optimal cut-off is calculated/reported, and participants are categorised according 
to this. 
 
Unclear: Insufficient information is provided to enable the reader to make a judgement as to 
whether the cut-off used was calculated to be an optimal cut-off on the basis of the 





13. Any withdrawals or exclusions from the study were explained 
 
Yes: No withdrawals and/or exclusions, OR the number of withdrawals and/or exclusions are 
clearly stated and explained and the possible impact of this is taken into account. 
 
No/Unclear: withdrawals and/or exclusions are referenced but not clearly described, and the 
reasons for this are not explained or accounted for in analysis. 
 
14. Statistical methods used to calculate and/or compare measures of diagnostic 
accuracy were appropriate 
 
Yes: Appropriate methods include: receiver operating characteristic for area under the curve 
(ROC/AUC); sensitivity and specificity; Odds Ratio (OR) positive predictive value (PPV) 
and negative predictive value (NPV), Youden Index. 
 
No: Clear absence of relevant diagnostic statistical data. Judgements of effectiveness of 
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index test are not based on above appropriate methods or are inaccurate  
 
Unclear: Insufficient information is provided to enable the reader to make a judgement as to 
appropriateness. 
 
15. The results of statistical methods used to assess diagnostic accuracy were reported 
in full 
 
Yes: the results of all stated tests are reported. Where some tests present a range of results 
(i.e. Youden index, ROC/AUC graph), these are reported in full.  
 
No: There is a clear absence of results for some statistical tests, OR tests which present a 
range of results are only partially reported. 
 
Unclear: Insufficient information is presented to enable the reader to make a judgement. 
 
16. Clinical and demographic characteristics of the study population were clearly 
reported and any differences were accounted for in statistical analysis 
 
Yes: Relevant4 clinical and demographic characteristics are reported in a clear format which 
enables comparison between groups (if more than one). Any population differences were 
reported and were accounted for in statistical analysis. 
4Relevant characteristics include: diagnostic classification; score on index test/comparator 
test; age; gender; education; ethnicity (if this would be considered relevant on the basis of 
the ethnic and cultural background of the study population) 
 
No: Clinical and demographic characteristics not reported in a clear format, OR key details 
are absent, OR significant group differences are present which are not accounted for in 
statistical analysis. 
 
Unclear: Insufficient information is provided to enable the reader to make a judgement  
 
17. Index tests scores were appropriately adjusted for education level 
 
Yes: One additional point is added for groups with less than 12 years education (as directed 
for original version of test) OR for translated versions, education is adjusted for using 
another approach which the reader judges to be sufficiently justified OR the reader judges 
that there is sufficient justification for not adjusting for educational differences. 
 
No: Education is not adjusted for using the instructions of the original test OR education is 
not adjusted for using an alternative method OR education is adjusted using a method which 
the reader would judge to be inappropriate or for which there is not an appropriate 
justification. 
 
Unclear: Insufficient information is provided to enable the reader to make a judgement. 
 
18. Estimates of diagnostic accuracy included measures of statistical uncertainty (e.g. 
95% confidence intervals)  
 
Yes: It is clear that all estimates of diagnostic accuracy (where appropriate) include measures 




No: Results are clearly presented without measures of statistical uncertainty, OR these are 
incomplete OR only some tests include measures of statistical uncertainty. 
 
Unclear: Insufficient information is presented to enable the reader to make a judgement. 
 
 
19. Optimal cut-off values were calculated and reported 
 
Yes: An optimal cut-off score balancing sensitivity and specificity was reported. 
 
No: only the pre-determined cut-off was used to report the sensitivity and specificity of the 
test with this population. 
 
Unclear: Insufficient information was provided to enable the reader to make a judgement. 
 
20. The clinical applicability of the study findings was discussed 
 
Yes: The discussion considers how the study findings might be applied in clinical practice. 
 
No: The discussion does not consider how study findings might be applied in clinical 
practice AND/OR only considers implications for further research. 
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Appendix B3 Study protocol version 10 approved by REC and R&D 
 
                                                                                                                  
 
Study Protocol: Psychological adjustment to a diagnosis of mild cognitive impairment: 
the roles of illness perceptions, cognitive functioning and psychological flexibility. 
 
 
People with mild cognitive impairment (MCI) are said to be at increased risk of developing 
dementia. MCI is associated with cognitive difficulties similar to those experienced by 
people with dementia, such as memory problems, but at attenuated levels (Petersen et al., 
1999). People with MCI also tend to have intact functional abilities (Petersen et al., 1999). 
Cognitive impairment can lead to perceptions of lower quality of life (QoL) and 
psychological wellbeing (Missotten et al., 2008; Selwood et al., 2005) but evidence is 
equivocal (Banerjee et al., 2009).   
 
Receiving a diagnosis of MCI can mean an uncertain prognosis and can be anxiety-
provoking, due to the increased risk of developing dementia. Recent research has indicated 
that the beliefs people hold about an illness can influence their quality of life (QoL) and 
psychological wellbeing (e.g. Jopson & Moss-Morris, 2003). People with MCI who hold 
negative beliefs about their diagnosis have been found to experience greater levels of 
emotional distress independently of their level of cognitive impairment (Lin et al., 2012; Lin 
& Heidrich, 2012). The impact on QoL is not currently understood. 
 
Evidence from studies evaluating the recently developed psychological intervention, 
Acceptance and Commitment Therapy (ACT; Hayes et al., 2006), indicates that how people 
stand towards their thoughts and beliefs, conceptualised here as psychological flexibility 
(PF), may play a role in how people respond to their thoughts. Thus, rather than reducing 
negative thinking overall, PF may act to reduce the impact of negative thoughts. For people 
with MCI who have negative perceptions about their illness, PF may therefore influence 
their perceived psychological wellbeing and QoL. 
 
Aims 
The current study aims to establish preliminary evidence for the possible utility of ACT for 
people with MCI by exploring (1) the relationship between illness perceptions of MCI, 
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psychological wellbeing and QoL in people with MCI (2) the relationship between level of 
cognitive impairment, psychological wellbeing and QoL in people with MCI and (3) whether 
illness appraisals are more strongly related to outcome variables than level of cognitive 
impairment and (4) whether these relationships are mediated by individual differences in PF. 
 
Research Questions  
 
 Do individual differences in PF have an effect on the relationships between 
illness appraisals, level of cognitive impairment, QoL and psychological 
wellbeing in people with MCI? 
 What is the nature of the relationship between appraisals of illness, QoL and 
psychological wellbeing in people with MCI? 
 What is the nature of the relationship between level of cognitive impairment, 
QoL and psychological wellbeing in people with MCI?  
 To establish whether illness appraisals are more strongly related to outcome 




The null hypotheses for the study will be: 
 
 There will be no significant relationships between: illness appraisals, QoL and 
psychological wellbeing, or between level of cognitive impairment, QoL and 
psychological wellbeing. 
 There will be no difference in the strength of relationships with outcome variables for 
illness appraisals and level of cognitive impairment. 
 Individual differences in PF will not mediate the relationships between illness 
appraisals, level of cognitive impairment, QoL and psychological wellbeing. 
 
The alternative hypotheses will therefore be: 
 
 There will be a significant relationship between: illness appraisals, QoL and 
psychological wellbeing and between level of cognitive impairment, QoL and 
psychological wellbeing. 
 Illness appraisals will be more strongly related to outcome variables than level of 
cognitive impairment. 
 Individual differences in PF will significantly influence the relationships between 





Method of investigation 
Participants 
Participants will be 53 individuals with mild cognitive impairment diagnosed within the past 




 Diagnosis of MCI within the past 3-6 months 
 Able to provide informed consent 
 Over the age of 60 
 Able to speak, read and write fluently in English 
 Absence of significant physical health problems (e.g. cancer) 
 No past history of brain injury (e.g. stroke, head trauma) 




 Premorbid cognitive difficulties (e.g. Learning disability) 
 Current residential or nursing care placement 
 Sensory impairment (e.g. blindness, deafness) 
 Current or past history of substance misuse 
 Current significant health problems 
 
Design 
A within-subjects, cross-sectional, questionnaire-based design will be employed to analyse the 
relationships between independent variables and outcome variables using statistical mediation 
analysis. All participants will complete seven questionnaires: a brief demographic 
questionnaire; the Montreal Cognitive Assessment (MoCA; Nasreddine et al., 2005); the 
Illness Perception Questionnaire – Mild Cognitive Impairment (IPQ-MCI; Lin et al., 2012); 
the Acceptance and Action Questionnaire-II (AAQ-II; Bond et al., 2011); the Geriatric 
Depression Scale-5 (GDS-5; Hoyl et al., 1999); the Geriatric Anxiety Inventory – Short Form 
(GAI-SF; Byrne & Pachana, 2011) and the Quality of Life in Alzheimer's Disease Scale (QOL-
AD; Logsdon et al., 2002). 
 
Measures 
The following measures will be used in this study: 
Demographic Questionnaire (created by principal researcher) 
All participants will complete a short questionnaire in order to gather basic information 





This is a measure of PF, a central tenet of ACT. It is a 7-item questionnaire containing 
statements to which participants assign a response based on a 7-point Likert scale ranging 
from: never true to always true. This scale has not been validated for use by people with MCI, 
though the original version of the AAQ has been used successfully with a sample of older 
people (Butler & Ciarrochi, 2007). 
 
Geriatric Depression Scale-5 
The GDS-5 is one of a number of shortened versions of the original GDS (GDS-30; Yesavage 
et al., 1983), providing a briefer administration time whilst maintaining high levels of 
sensitivity, specificity, accuracy and predictive ability (Hoyl et al., 1999). The GDS-5 has been 
successfully used by people with mild to moderate dementia (e.g. Lach et al., 2010). The scale 
consists of 5 items which respondents either endorse or reject by answering yes or no. 
 
Geriatric Anxiety Inventory-SF 
The GAI-SF is a shortened form of the original Geriatric Anxiety Inventory (GAI; Pachana et 
al., 2007). Though the longer GAI is argued to have more robust psychometrics (Byrne & 
Pachana, 2011), the use of the GAI-SF in this case is to minimise fatigue and item burden to 
participants. The GAI-SF has not been employed with a population of people with MCI; 
however, the longer GAI has been employed with a sample of memory clinic attendees (Byrne 
et al., 2008). The GAI-SF consists of 5 items to which respondents indicate their agreement or 
disagreement by answering yes or no. 
 
Quality of Life in Alzheimer's Disease 
The QoL-AD was identified as a reliable and valid self-report tool (Logsdon et al., 2002) that 
has been utilised widely as an outcome measure in research with people with dementia and 
cognitive impairment. This is a 13-item scale assessing various QoL contributors, such as 
living situation, and ability to do things for fun. Respondents rate each factor on a 4-point 
Likert scale ranging from poor to excellent. 
 
IPQ-MCI 
The IPQ-MCI is a version of the revised Illness Perception Questionnaire (IPQ-R; Moss-
Morris et al., 2002) developed and piloted for use with people with MCI comprising 8 
subscales and 88 items in total. Participants are given a range of possible symptoms and asked 
to tick which ones they have experienced as a result of their MCI. They then rate a number of 
statements about their illness beliefs from a five point Likert scale ranging from Strongly agree 





The MoCA is a brief cognitive screening tool taking approximately 10 minutes to administer. 
Participants are scored out of 30 on tasks purporting to measure a number of cognitive 
domains, including memory, attention, visuospatial functioning, language and executive 
functioning. The MoCA was developed in order to produce a cognitive screen with greater 
sensitivity to MCI and early dementia than more commonly used tools such as the Mini-Mental 
State Examination (MMSE; Folstein et al., 1975), supported by findings from recent studies 




Participants identified as meeting inclusion/exclusion criteria by NHS clinical staff 
(Psychiatry, Clinical Psychology, Community Psychiatric Nursing) will be approached within 
the context of clinical appointments by their named clinician, who will provide a verbal outline 
of the study and invite them to participate. If participants indicate an interest in becoming 
involved in the study, their named clinician will provide them with a participant information 
sheet (PIS) and an invitation letter. At this time the clinician will also inform them that the 
Chief Investigator will contact them by telephone to discuss the study further and to arrange 
an appointment following a minimum of twenty four hours. 
 
Casenote review: 
The Chief Investigator (who will be employed as a Trainee Clinical Psychologist within the 
service) will conduct a casenote review of patients recently diagnosed with MCI to identify 
possible participants who meet inclusion/exclusion criteria. Where possible, when such 
patients have a caseholder, their named clinician will approach them to invite them to 
participate. They will then be provided with a PIS and invitation letter. Where patients do not 
have an active caseholder, they will be sent an invitation letter and PIS. The PIS will include 
a reply slip to enable participants to register their interest in taking part and to opt in to 
receiving contact from the researcher. Participants will be informed that once their reply slip 
has been received, the Chief Investigator will contact them by telephone to discuss the study 
further and to arrange an appointment.  
 
Procedure 
Once participants have agreed to be contacted, the Chief Investigator will contact them by 
telephone to discuss the study further and to arrange an interview appointment. All 
appointments will take place at NHS Lothian sites, at the Royal Edinburgh Hospital, 
Edinburgh, at St. John's Hospital, Livingston, at Musselburgh Primary Care Centre, 
Musselburgh or at Herdmanflat Hospital, Haddington. Interview appointments will last 
approximately one hour. Each appointment will consist of the following: 
 
 Seeking informed consent (5 minutes) 
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 Completion of demographic questionnaire (5 minutes) 
 Completion of cognitive screening measure – those scoring below clinical cut off for 
dementia on the MoCA will be removed from the study and their GP informed (10 
minutes) 
 Assessment of mood (5 minutes) 
 Assessment of anxiety (5 minutes) 
 Assessment of illness appraisals (10 minutes) 
 Assessment of PF (5 minutes) 
 Assessment of QoL (10 minutes) 
 Participant questions/comments and debrief (5 minutes) 
 





Should participants wish to take a short break, they will be offered the opportunity to do so. If 
participants become distressed or feel fatigued, they will have the option of rescheduling the 
appointment or discontinuing their involvement in the study. Appropriate steps will be taken 
to minimise risk of harm should participants report distress. The Chief Investigator, as a 
Trainee Clinical Psychologist, is competent in the core skills necessary to provide immediate 
comfort and psychological support, and participants will be advised to seek further advice 
from their GP should they have any concerns about their mental and/or cognitive health. If 
significant concerns are raised regarding a participant's mental health, the Chief Investigator 
will seek advice from the project clinical supervisor and will provide immediate support, the 
participant's GP will be informed and they will be removed from the study. The Chief 
Investigator will be working under the supervision of a qualified Clinical Psychologist, and 
will be able to seek further advice from them if necessary. In addition, as part of the clinical 
team, the Chief Investigator will be able to facilitate access to psychological support and other 
treatments from the wider Older Adult Mental Health Service for participants if necessary. 
 
Statistical Analysis 
Initial correlational analyses will be carried out in order to establish the relationships between 
variables in the statistical model. Any variables not correlated will be removed from the model. 
The main research questions and objectives will be examined through mediation analysis, 
calculated using bias-corrected bootstrapping techniques, with separate analyses being carried 
out for each independent and dependent variable. Therefore, a total of six mediation analyses 
will be calculated. The independent variables are: level of cognitive impairment and illness 




The study will be written up as a doctoral thesis in line with the requirements of the University 
of Edinburgh Doctorate in Clinical Psychology. The thesis will also include a write up of the 
study in peer-reviewed journal format which will be prepared for publication in a relevant 
journal. A brief summary of the findings of the study will also be compiled and sent out to any 
participants who indicated their interest in receiving this on the consent form. Presentations 
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PARTICIPANT INFORMATION SHEET 
 
 
STUDY TITLE: Psychological adjustment to mild cognitive impairment 
You are being invited to take part in a research study. Before you decide if you would like to 
participate, it is important for you to understand why the research is being done and what it 
would involve for you. Please take time to read the following information carefully, and talk 
to others about the study if you wish. If there is anything that is unclear, or if you have any 
questions, please do not hesitate to ask the Chief Investigator (Amanda Stevenson). You can 
also contact them using the details at the end of this sheet. 
 
WHAT IS THE RESEARCH ABOUT? 
This study is examining how people adjust to receiving a diagnosis of mild cognitive 
impairment (sometimes referred to as memory and thinking difficulties). We know that how 
people view their diagnosis or condition can affect their sense of wellbeing, but the ways in 
which psychological factors influence the relationship between views about a condition and 
wellbeing are not well understood.  
 
WHY HAVE I BEEN INVITED? 
We are inviting people who have received a diagnosis of mild cognitive impairment within the 
past three to six months to take part. We are aiming to recruit between 50 and 60 participants. 
 
DO I HAVE TO TAKE PART? 
No. It is up to you to decide whether or not to join this study.  
 
If you do decide to participate, you will be asked to sign a consent form, and you will be able 
to keep this information sheet for reference. If you decide to take part you will still be able to 




Involvement with the study will not affect the care you receive from any NHS service, now, 
or in the future (whether or not you decide to participate). 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
If you choose to take part in this study, you will be asked to meet with the Chief Investigator 
on one occasion to participate in an individual interview lasting approximately one hour. The 
appointment will take place at one of the following locations: Royal Edinburgh Hospital, 
Edinburgh; St John's Hospital, Livingston; Musselburgh Primary Care Centre, Musselburgh; 
Herdmanflat Hospital, Haddington. You will be able to choose which one would be most 
convenient for you, along with a time and date which is suitable for you. Please note that 
unfortunately we are unable to reimburse your travel expenses.  
 
During the appointment you will have a further opportunity to ask questions and to discuss 
your involvement in the study. If you still wish to participate, you will be asked to sign a 
consent form stating that you agree to participate and that you understand what your 
participation will entail. We will also inform your GP (General Practitioner) by letter that you 
are taking part in the study.  
 
You will then be asked to complete a series of questionnaires with the assistance of the Chief 
Investigator including: 
 
 A brief test of mental functioning, such as memory 
 Your views regarding your diagnosis of mild cognitive impairment and your current 
mental health 
 
If at any point during the appointment you no longer wish to take part, you may withdraw from 
the study without having to give a reason. 
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
It is likely that there will not be an immediate benefit to you, but your participation will aid in 
our understanding of how people adjust to mild cognitive impairment. This may inform the 
development of future psychological treatments and interventions for people with mild 
cognitive impairment.  
 
WHAT ARE THE POSSIBLE RISKS AND DISADVANTAGES OF TAKING PART? 
You will be asked to complete a set of seven tasks and questionnaires over a period of 
approximately one hour, which can leave some people feeling tired. In addition, some 
questions will ask you about sensitive topics, particularly regarding your current mental health, 
and your views about your diagnosis of mild cognitive impairment. It is possible that thinking 




If you should experience either of these then you should inform the Chief Investigator, who 
will offer you support and ask whether you would like to take a break or to reschedule a later 
appointment. If you should become upset, or have any concerns, the Chief Investigator will be 
able to provide you with immediate comfort and support. We may also need to inform your 
GP or involve someone else who can help, such as a Psychiatrist. 
 
WHAT HAPPENS WHEN THE RESEARCH STUDY STOPS? 
Consent forms and identifiable information will be destroyed, but your anonymous data may 
be held for future authorised research.  
 
WILL MY TAKING PART IN THE STUDY BE KEPT CONFIDENTIAL? 
All the information we collect from you will be kept confidential. We will keep your data 
anonymous during the research by assigning it a unique reference number. This reference 
number will be the only link between your data and your consent form. Once the study has 
been completed, your consent form will be destroyed. Your data will be securely stored on an 
NHS site and will be kept separately from consent forms. 
 
Your data will only be accessible to the Chief Investigator, study supervisors, and anyone 
appointed by the Sponsor (NHS Lothian/University of Edinburgh) to ensure the study is being 
carried out correctly. 
 
We will inform your GP of your participation in the study by letter; however, we will not 
provide details to your GP regarding your performance on the assessment task or of your 
responses to questionnaires, unless you report any significant difficulties with your mood or 
functioning.  
 
If you report anything that makes the Chief Investigator consider that you, or someone you 
know, are at risk of harm, your GP would need to be informed and we may need to involve 
someone else who can help, such as a Psychiatrist. Similarly, if you report information that 
relates to the prevention or detection of crime, the Chief Investigator may be required to 
disclose this information to relevant agencies (eg. Police). In each case, the Chief Investigator 
would discuss with you how this might be addressed. 
  
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? 
The results of the study will be written up and reported in a doctoral thesis format in part 
fulfilment of the requirements of the University of Edinburgh Doctorate in Clinical 
Psychology. We also hope to submit this thesis project to relevant academic journals for 
publication. All the information we collect from you will be kept anonymous, and will only 




If you would like to be informed of the results of the study, you may indicate your preference 
when signing the study consent form. You will then be provided with a written summary 
following completion of the study in May 2014. 
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
The study is being organised by Amanda Stevenson, Trainee Clinical Psychologist, under the 
supervision of Dr. David Gillanders (University of Edinburgh), Dr. Nuno Ferreira (University 
of Edinburgh) and Dr. Donna Gilroy (NHS Lothian). The study is being supported by both 
NHS Lothian and the University of Edinburgh.  
 
WHO HAS REVIEWED THE STUDY? 
The project proposal has been reviewed and accepted by the University of Edinbugh Doctorate 
in Clinical Psychology, and by my supervisors: Dr. David Gillanders (Academic Director, 
Doctorate in Clinical Psychology), Dr. Nuno Ferreira (Lecturer in Clinical Psychology) and 
Dr. Donna Gilroy (Clinical Psychologist). Ethical approval has been granted by South East 
Scotland Research Ethics Committee on 21/01/14. 
 
WHAT TO DO NOW? 
Since you have indicated to a member of staff that you are interested in participating, the Chief 
Investigator will contact you by telephone in the coming weeks to discuss the study with 
you and to arrange an interview appointment.  
 
Alternatively, you may contact the Chief Investigator using the below details: 
Amanda Stevenson 
Trainee Clinical Psychologist 
Older Adult Psychology Service 






If you would like to speak to someone else about the study, please contact: 
 
Dr Heather Wilkinson 
Research Director 
School of Health in Social Science 







WHAT IF SOMETHING GOES WRONG? 
If you should wish to make a formal complaint regarding the study, please contact:  
 
NHS Lothian Complaints Team 
Waverley Gate 
2nd Floor 
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 




Fig. 1: Flow chart explaining participation process 
 
                 Thank you for taking the time to read this information sheet 
                              Amanda Stevenson, Trainee Clinical Psychologist 
 
Amanda Stevenson will contact you by 
telephone to ask you if you if you would 
like to discuss the study further and to 
ask you if you would like to participate
I do not wish to participate: You 
may inform Amanda Stevenson at 
this point. You do not need to do 
anything else.
I would like to discuss the study 
further or would like to discuss 
how I can participate: You may ask 
Amanda Stevenson any questions 
you wish at this point.
I would like to 
participate
Arrange a time, date and location 
to complete the interview 
appointment. Your GP will be 




I do not wish to 
participate: Please inform 
Amanda Stevenson that 
you no longer wish to take 
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PARTICIPANT INFORMATION SHEET 
 
 
STUDY TITLE: Psychological adjustment to mild cognitive impairment 
 
You are being invited to take part in a research study. Before you decide if you would like to 
participate, it is important for you to understand why the research is being done and what it 
would involve for you. Please take time to read the following information carefully, and talk 
to others about the study if you wish. If there is anything that is unclear, or if you have any 
questions, please do not hesitate to ask the Chief Investigator (Amanda Stevenson). You can 
also contact them using the details at the end of this sheet. 
 
WHAT IS THE RESEARCH ABOUT? 
This study is examining how people adjust to receiving a diagnosis of mild cognitive 
impairment (sometimes referred to as memory and thinking difficulties). We know that how 
people view their diagnosis or condition can affect their sense of wellbeing, but the ways in 
which psychological factors influence the relationship between views about a condition and 
wellbeing are not well understood.  
 
WHY HAVE I BEEN INVITED? 
We are inviting people who have received a diagnosis of mild cognitive impairment within the 
past three to six months to take part. We are aiming to recruit between 50 and 60 participants. 
 
DO I HAVE TO TAKE PART? 
No. It is up to you to decide whether or not to join this study.  
 
If you do decide to participate, you will be asked to sign a consent form, and you will be able 
to keep this information sheet for reference. If you decide to take part you will still be able to 
withdraw from the study at any point and you do not have to give a reason.  
 
Involvement with the study will not affect the care you receive from any NHS service, now, 
or in the future (whether or not you decide to participate). 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
If you choose to take part in this study, you will be asked to meet with the Chief Investigator 
on one occasion to participate in an individual interview lasting approximately one hour. The 
appointment will take place at one of the following locations: Royal Edinburgh Hospital, 
Edinburgh; St John's Hospital, Livingston; Musselburgh Primary Care Centre, Musselburgh; 
Herdmanflat Hospital, Haddington. You will be able to choose which one would be most 
convenient for you, along with a time and date which is suitable for you. Please note that 




During the appointment you will have a further opportunity to ask questions and to discuss 
your involvement in the study. If you still wish to participate, you will be asked to sign a 
consent form stating that you agree to participate and that you understand what your 
participation will entail. We will also inform your GP (General Practitioner) by letter that you 
are taking part in the study.  
 
You will then be asked to complete a series of questionnaires with the assistance of the Chief 
Investigator including: 
 
 A brief test of mental functioning, such as memory 
 Your views regarding your diagnosis of mild cognitive impairment and your current 
mental health 
 
If at any point during the appointment you no longer wish to take part, you may withdraw from 
the study without having to give a reason. 
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
It is likely that there will not be an immediate benefit to you, but your participation will aid in 
our understanding of how people adjust to mild cognitive impairment. This may inform the 
development of future psychological treatments and interventions for people with mild 
cognitive impairment.  
 
WHAT ARE THE POSSIBLE RISKS AND DISADVANTAGES OF TAKING PART? 
You will be asked to complete a set of seven tasks and questionnaires over a period of 
approximately one hour, which can leave some people feeling tired. In addition, some 
questions will ask you about sensitive topics, particularly regarding your current mental health, 
and your views about your diagnosis of mild cognitive impairment. It is possible that thinking 
about these issues may cause some to feel upset or distressed.  
 
If you should experience either of these then you should inform the Chief Investigator, who 
will offer you support and ask whether you would like to take a break or to reschedule a later 
appointment. If you should become upset, or have any concerns, the Chief Investigator will be 
able to provide you with immediate comfort and support. We may also need to inform your 
GP or involve someone else who can help, such as a Psychiatrist. 
 
WHAT HAPPENS WHEN THE RESEARCH STUDY STOPS? 
Consent forms and identifiable information will be destroyed, but your anonymous data may 
be held for future authorised research.  
 
WILL MY TAKING PART IN THE STUDY BE KEPT CONFIDENTIAL? 
All the information we collect from you will be kept confidential. We will keep your data 
anonymous during the research by assigning it a unique reference number. This reference 
number will be the only link between your data and your consent form. Once the study has 
been completed, your consent form will be destroyed. Your data will be securely stored on an 
NHS site and will be kept separately from consent forms. 
 
Your data will only be accessible to the Chief Investigator, study supervisors, and anyone 
appointed by the Sponsor (NHS Lothian/University of Edinburgh) to ensure the study is being 
carried out correctly. 
 
We will inform your GP of your participation in the study by letter; however, we will not 
provide details to your GP regarding your performance on the assessment task or of your 
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responses to questionnaires, unless you report any significant difficulties with your mood or 
functioning.  
 
If you report anything that makes the Chief Investigator consider that you, or someone you 
know, are at risk of harm, your GP would need to be informed and we may need to involve 
someone else who can help, such as a Psychiatrist. Similarly, if you report information that 
relates to the prevention or detection of crime, the Chief Investigator may be required to 
disclose this information to relevant agencies (eg. Police). In each case, the Chief Investigator 
would discuss with you how this might be addressed. 
  
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? 
The results of the study will be written up and reported in a doctoral thesis format in part 
fulfilment of the requirements of the University of Edinburgh Doctorate in Clinical 
Psychology. We also hope to submit this thesis project to relevant academic journals for 
publication. All the information we collect from you will be kept anonymous, and will only 
be identifiable to the Chief Investigator and study supervisors. 
 
If you would like to be informed of the results of the study, you may indicate your preference 
when signing the study consent form. You will then be provided with a written summary 
following completion of the study in May 2014. 
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
The study is being organised by Amanda Stevenson, Trainee Clinical Psychologist, under the 
supervision of Dr. David Gillanders (University of Edinburgh), Dr. Nuno Ferreira (University 
of Edinburgh) and Dr. Donna Gilroy (NHS Lothian). The study is being supported by both 
NHS Lothian and the University of Edinburgh.  
 
WHO HAS REVIEWED THE STUDY? 
The project proposal has been reviewed and accepted by the University of Edinbugh Doctorate 
in Clinical Psychology, and by my supervisors: Dr. David Gillanders (Academic Director, 
Doctorate in Clinical Psychology), Dr. Nuno Ferreira (Lecturer in Clinical Psychology) and 
Dr. Donna Gilroy (Clinical Psychologist). Ethical approval has been granted by South East 
Scotland Research Ethics Committee on dd/mm/yy. 
 
WHAT TO DO NOW? 
If you would like to know more about the study or are interested in participating, please contact 
the Chief Investigator using the reply slip at the end of this sheet. Amanda Stevenson will then 
contact you by telephone to discuss the study with you and to arrange an appointment should 
you decide to participate. 
 
FURTHER INFORMATION 
If you would like to speak to someone else about the study, please contact: 
 
Dr Heather Wilkinson 
Research Director 
School of Health in Social Science 









WHAT IF SOMETHING GOES WRONG? 
 
If you should wish to make a formal complaint regarding the study, please contact:  
 
NHS Lothian Complaints Team 
Waverley Gate 
2nd Floor 
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 





Fig. 1: Flow chart explaining participation process 
 
 
Thank you for taking the time to read this information sheet. Amanda Stevenson, Trainee 
Clinical Psychologist 
Contact Amanda Stevenson using above 
details or complete the reply slip and 
send to the above address.
A researcher will contact you by telephone 
to discuss the study further with you.
I would like to 
participate
Arrange a time, date and location 
to complete the interview 
appointment. Your GP will be 




I do not wish to 
participate: Please inform 
Amanda Stevenson that 
you no longer wish to take 
part. You do not have to 
provide a reason.
I would like further information or 
would like to discuss how I can 
participate in the study.
I do not wish to 
participate.
You do not need to do 
anything else. Thank you 





If you would like to participate in the study, or would like a researcher to contact you 
to discuss the study, please complete the tear off slip below and send it to: 
 
Amanda Stevenson 
Trainee Clinical Psychologist 
Older Adult Psychology Service 
Psychology Department 



















Psychological adjustment to mild cognitive impairment 
 
Dear Name of potential participant, 
 
My name is Amanda Stevenson, I am a Trainee Clinical Psychologist with NHS 
Lothian and am currently a doctoral student of Clinical Psychology at the University 
of Edinburgh. In line with the requirements of my training, I am conducting a study 
to investigate the process of psychological adjustment to a diagnosis of mild 
cognitive impairment. 
 
I am writing to inform you of the study and to invite you to take part because you 
have been diagnosed with mild cognitive impairment within the past three to six 
months and because you have indicated to a clinician that you would like to hear 
more about the study.  
 
Enclosed is a Participant Information Sheet which will tell you why the study is 
being carried out and what would be required from you if you decide to take part. 
 
Please take some time to read and consider the following information carefully. You 
might find it helpful to show it to family and friends and to discuss it with them. I 
would like to make you aware that you are not obliged to participate in this study, 
and that this will not affect your current or future care in any way whether you 
decide to join the study or not. If you do decide to take part, you will still be able to 
end your participation at any time without having to give a reason. 
 
I will contact you by telephone within the next two weeks to ask you whether or not 
you wish to be involved and to answer any questions you might have. Alternatively, 
you may contact me using the details on the information sheet. 
 





Amanda Stevenson                                           Supervised by Dr. Donna Gilroy 














Psychological adjustment to mild cognitive impairment 
 
Dear Name of potential participant, 
 
My name is Amanda Stevenson, I am a Trainee Clinical Psychologist with NHS 
Lothian and am currently a doctoral student of Clinical Psychology at the University 
of Edinburgh. In line with the requirements of my training, I am conducting a study 
to investigate the process of psychological adjustment to a diagnosis of mild 
cognitive impairment. 
 
I am writing to inform you of the study and to invite you to take part because a recent 
review of memory clinic attendance indicated that you were diagnosed with mild 
cognitive impairment within the past three to six months.  
 
Enclosed is a Participant Information Sheet which will tell you why the study is 
being carried out and what would be required from you if you decide to take part. 
 
Please take some time to read and consider the following information carefully. You 
might find it helpful to show it to family and friends and to discuss it with them. I 
would like to make you aware that you are not obliged to participate in this study, 
and that this will not affect your current or future care in any way whether you 
decide to join the study or not. If you do decide to take part, you will still be able to 
end your participation at any time without having to give a reason. 
 
If you would like to take part, or would like to discuss the study in more detail, 
please complete the reply slip at the bottom of the Participant Information Sheet. 
You will then be contacted by telephone to answer any questions you might have and 
to arrange an appointment should you decide to take part. 
 





Amanda Stevenson                                                 Supervised by Dr. Donna Gilroy 















Dear name of General Practitioner, 
 
RE: Name, DOB, CHI, Address of patient. 
 
I am writing to inform you that the above named patient has consented to be take part in my 
research project. The study is investigating various cognitive and psychological factors that 
may affect how well an individual adjusts to a diagnosis of mild cognitive impairment. I am 
conducting this project in part fulfilment of the Doctorate in Clinical Psychology at the 
University of Edinburgh. It has been granted ethical approval by South East Scotland 
Research Ethics Committee (21/01/14).  
 
The above named patient has been invited to take part in the study through their involvement 
with memory clinic services across NHS Lothian. They may have been approached because 
they have indicated to a service clinician that they are interested in participating or because 
they have been identified as meeting study inclusion/exclusion criteria through casenote 
review. We are recruiting individuals with a diagnosis of mild cognitive impairment given in 
the past three to six months. 
 
Involvement in the research will require participants to complete a series of measures 
assessing cognitive functioning and various psychological factors, including mood. 
Participants will attend an appointment lasting up to one hour; however, in order to reduce 
the potential for fatigue, they will be offered the opportunity to take breaks if they should 
wish. 
 
I will not inform GPs of patients' performance on study measures as a matter of routine; 
however, should any concerns be raised regarding mood, anxiety, further cognitive 
impairment or risk of harm to self or others, you will be contacted directly. 
 







Amanda Stevenson                                                            Supervised by Dr Donna Gilroy 
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Submit manuscripts electronically through the Manuscript Submission Portal (.rtf, 
.doc, or .pdf files). 
Ulrich Mayr  
Department of Psychology  
University of Oregon  
Eugene, OR 
General correspondence may be directed to the Editor's Office. 
In addition to addresses and phone numbers, please supply email addresses and fax 
numbers, if available, for potential use by the editorial office and later by the 
production office. 
Masked review 
Masked reviews are optional, and authors who wish masked reviews must specifically 
request them at submission. Authors requesting masked review should make every 
effort to see that the manuscript itself contains no clues to their identities. Authors' 
names, affiliations, and contact information should be included only in the cover letter. 
If your manuscript was mask reviewed, please ensure that the final version for 
production includes a byline and full author note for typesetting. 
Length 
Manuscripts should not exceed 8,000 words (approximately 27 double-spaced pages 
in 12-point Times New Roman font). Shorter manuscripts are equally welcomed. 
The word count does not include references, tables, and figures. If you feel that you 
need extra space, please contact the editor. For example, you may have a complex 
methodology or statistical approach or a new theoretical framework that requires more 
text. 




The Brief Report format is designated for particularly "crisp," theoretically noteworthy 
contributions that meet highest methodological standards. Use 12-point Times New 
Roman type and 1-inch (2.54-cm) margins; include an abstract of 75–100 words; do 
not exceed 265 lines of text, not including references; and typically include no more 
than two tables or figures. 
Manuscript preparation 
Prepare manuscripts according to the Publication Manual of the American 
Psychological Association (6th edition). Manuscripts may be copyedited for bias-free 
language (see Chapter 3 of the Publication Manual). 
Review APA's Checklist for Manuscript Submission before submitting your article. 
Double-space all copy. Other formatting instructions, as well as instructions on 
preparing tables, figures, references, metrics, and abstracts, appear in the Manual. 
Below are additional instructions regarding the preparation of display equations, 
computer code, and tables.  
Display equations 
We strongly encourage you to use MathType (third-party software) or Equation Editor 
3.0 (built into pre-2007 versions of Word) to construct your equations, rather than the 
equation support that is built into Word 2007 and Word 2010. Equations composed 
with the built-in Word 2007/Word 2010 equation support are converted to low-
resolution graphics when they enter the production process and must be rekeyed by 
the typesetter, which may introduce errors. 
To construct your equations with MathType or Equation Editor 3.0: 
 Go to the Text section of the Insert tab and select Object. 
 Select MathType or Equation Editor 3.0 in the drop-down menu. 
If you have an equation that has already been produced using Microsoft Word 2007 or 
2010 and you have access to the full version of MathType 6.5 or later, you can convert 
this equation to MathType by clicking on MathType Insert Equation. Copy the 
equation from Microsoft Word and paste it into the MathType box. Verify that your 
equation is correct, click File, and then click Update. Your equation has now been 
inserted into your Word file as a MathType Equation. 
Use Equation Editor 3.0 or MathType only for equations or for formulas that cannot 
be produced as Word text using the Times or Symbol font. 
Computer code 
Because altering computer code in any way (e.g., indents, line spacing, line breaks, 
page breaks) during the typesetting process could alter its meaning, we treat computer 
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code differently from the rest of your article in our production process. To that end, 
we request separate files for computer code. 
In Online Supplemental Material  
We request that runnable source code be included as supplemental material to the 
article. For more information, visit Supplementing Your Article With Online 
Material. 
In the Text of the Article  
If you would like to include code in the text of your published manuscript, please 
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Study Protocol: Psychological adjustment to a diagnosis of mild cognitive impairment: 
the roles of illness perceptions, cognitive functioning and psychological flexibility. 
 
People with mild cognitive impairment (MCI) are said to be at increased risk of developing 
dementia. MCI is associated with cognitive difficulties similar to those experienced by 
people with dementia, such as memory problems, but at attenuated levels (Petersen et al., 
1999). People with MCI also tend to have intact functional abilities (Petersen et al., 1999). 
Cognitive impairment can lead to perceptions of lower quality of life (QoL) and 
psychological wellbeing (Missotten et al., 2008; Selwood et al., 2005) but evidence is 
equivocal (Banerjee et al., 2009).  
 
Receiving a diagnosis of MCI can mean an uncertain prognosis and can be anxiety-
provoking, due to the increased risk of developing dementia. Recent research has indicated 
that the beliefs people hold about an illness can influence their quality of life (QoL) and 
psychological wellbeing (e.g. Jopson & Moss-Morris, 2003). People with MCI who hold 
negative beliefs about their diagnosis have been found to experience greater levels of 
emotional distress independently of their level of cognitive impairment (Lin et al., 2012; Lin 
& Heidrich, 2012). The impact on QoL is not currently understood. 
 
Evidence from studies evaluating the recently developed psychological intervention, 
Acceptance and Commitment Therapy (ACT; Hayes et al., 2006), indicates that how people 
stand towards their thoughts and beliefs, conceptualised here as psychological flexibility 
(PF), may play a role in how people respond to their thoughts. Thus, rather than reducing 
negative thinking overall, PF may act to reduce the impact of negative thoughts. For people 
with MCI who have negative perceptions about their illness, PF may therefore influence 
their perceived psychological wellbeing and QoL. 
Aims 
The current study aims to establish preliminary evidence for the possible utility of ACT for 
people with MCI by exploring (1) the relationship between illness perceptions of MCI, 
psychological wellbeing and QoL in people with MCI (2) the relationship between level of 
cognitive impairment, psychological wellbeing and QoL in people with MCI and (3) whether 
illness appraisals are more strongly related to outcome variables than level of cognitive 




Research Questions  
 Do individual differences in PF have an effect on the relationships between illness 
appraisals, level of cognitive impairment, QoL and psychological wellbeing in 
people with MCI? 
 What is the nature of the relationship between appraisals of illness, QoL and 
psychological wellbeing in people with MCI? 
 What is the nature of the relationship between level of cognitive impairment, QoL 
and psychological wellbeing in people with MCI?  
 To establish whether illness appraisals are more strongly related to outcome 
variables than level of cognitive impairment. 
 
Hypotheses 
The null hypotheses for the study will be: 
 There will be no significant relationships between: illness appraisals, QoL and 
psychological wellbeing, or between level of cognitive impairment, QoL and 
psychological wellbeing. 
 There will be no difference in the strength of relationships with outcome variables 
for illness appraisals and level of cognitive impairment. 
 Individual differences in PF will not mediate the relationships between illness 
appraisals, level of cognitive impairment, QoL and psychological wellbeing. 
The alternative hypotheses will therefore be: 
 There will be a significant relationship between: illness appraisals, QoL and 
psychological wellbeing and between level of cognitive impairment, QoL and 
psychological wellbeing. 
 Illness appraisals will be more strongly related to outcome variables than level of 
cognitive impairment. 
 Individual differences in PF will significantly influence the relationships between 
illness appraisals, level of cognitive impairment, QoL and psychological wellbeing. 
 
Method of investigation 
Participants 
Participants will be 53 individuals with mild cognitive impairment diagnosed within the past 






 Diagnosis of MCI within the past 9 months 
 Able to provide informed consent 
 Over the age of 60 
 Able to speak, read and write fluently in English 
 Absence of significant physical health problems (e.g. cancer) 
 No past history of brain injury (e.g. head trauma) 
 No current psychiatric diagnosis (e.g. psychosis) 
 
Exclusion criteria 
 Premorbid cognitive difficulties (e.g. Learning disability) 
 Current residential or nursing care placement 
 Sensory impairment (e.g. blindness, deafness) 
 Current or past history of substance misuse 
 Current significant health problems 
 
Design 
A within-subjects, cross-sectional, questionnaire-based design will be employed to analyse 
the relationships between independent variables and outcome variables using statistical 
mediation analysis. All participants will complete seven questionnaires: a brief demographic 
questionnaire; the Montreal Cognitive Assessment (MoCA; Nasreddine et al., 2005); the 
Illness Perception Questionnaire – Mild Cognitive Impairment (IPQ-MCI; Lin et al., 2012); 
the Acceptance and Action Questionnaire-II (AAQ-II; Bond et al., 2011); the Geriatric 
Depression Scale-5 (GDS-5; Hoyl et al., 1999); the Geriatric Anxiety Inventory – Short 
Form (GAI-SF; Byrne & Pachana, 2011) and the Quality of Life in Alzheimer's Disease 
Scale (QOL-AD; Logsdon et al., 2002). 
Measures 
The following measures will be used in this study: 
Demographic Questionnaire (created by principal researcher) 
All participants will complete a short questionnaire in order to gather basic information 
regarding sample population demographics. No personal information will be gathered. 
AAQ-II 
This is a measure of PF, a central tenet of ACT. It is a 7-item questionnaire containing 
statements to which participants assign a response based on a 7-point Likert scale ranging 
from: never true to always true. This scale has not been validated for use by people with 
MCI, though the original version of the AAQ has been used successfully with a sample of 





Geriatric Depression Scale-5 
The GDS-5 is one of a number of shortened versions of the original GDS (GDS-30; 
Yesavage et al., 1983), providing a briefer administration time whilst maintaining high levels 
of sensitivity, specificity, accuracy and predictive ability (Hoyl et al., 1999). The GDS-5 has 
been successfully used by people with mild to moderate dementia (e.g. Lach et al., 2010). 
The scale consists of 5 items which respondents either endorse or reject by answering yes or 
no. 
Geriatric Anxiety Inventory-SF 
The GAI-SF is a shortened form of the original Geriatric Anxiety Inventory (GAI; Pachana 
et al., 2007). Though the longer GAI is argued to have more robust psychometrics (Byrne & 
Pachana, 2011), the use of the GAI-SF in this case is to minimise fatigue and item burden to 
participants. The GAI-SF has not been employed with a population of people with MCI; 
however, the longer GAI has been employed with a sample of memory clinic attendees 
(Byrne et al., 2008). The GAI-SF consists of 5 items to which respondents indicate their 
agreement or disagreement by answering yes or no. 
Quality of Life in Alzheimer's Disease 
The QoL-AD was identified as a reliable and valid self-report tool (Logsdon et al., 2002) that 
has been utilised widely as an outcome measure in research with people with dementia and 
cognitive impairment. This is a 13-item scale assessing various QoL contributors, such as 
living situation, and ability to do things for fun. Respondents rate each factor on a 4-point 
Likert scale ranging from poor to excellent. 
IPQ-MCI 
The IPQ-MCI is a version of the revised Illness Perception Questionnaire (IPQ-R; Moss-
Morris et al., 2002) developed and piloted for use with people with MCI comprising 8 
subscales and 88 items in total. Participants are given a range of possible symptoms and 
asked to tick which ones they have experienced as a result of their MCI. They then rate a 
number of statements about their illness beliefs from a five point Likert scale ranging from 
Strongly agree to Strongly disagree.  
MoCA 
The MoCA is a brief cognitive screening tool taking approximately 10 minutes to 
administer. Participants are scored out of 30 on tasks purporting to measure a number of 
cognitive domains, including memory, attention, visuospatial functioning, language and 
executive functioning. The MoCA was developed in order to produce a cognitive screen with 
greater sensitivity to MCI and early dementia than more commonly used tools such as the 
Mini-Mental State Examination (MMSE; Folstein et al., 1975), supported by findings from 








Participants identified as meeting inclusion/exclusion criteria by NHS clinical staff 
(Psychiatry, Clinical Psychology, Community Psychiatric Nursing) will be approached 
within the context of clinical appointments by their named clinician, who will provide a 
verbal outline of the study and invite them to participate. If participants indicate an interest 
in becoming involved in the study, their named clinician will provide them with a participant 
information sheet (PIS) and an invitation letter. At this time the clinician will also inform 
them that the Chief Investigator will contact them by telephone to discuss the study further 
and to arrange an appointment following a minimum of twenty four hours. 
Casenote review: 
The Chief Investigator (who will be employed as a Trainee Clinical Psychologist within the 
service) will conduct a casenote review of patients recently diagnosed with MCI to identify 
possible participants who meet inclusion/exclusion criteria. Where possible, when such 
patients have a caseholder, their named clinician will approach them to invite them to 
participate. They will then be provided with a PIS and invitation letter. Where patients do not 
have an active caseholder, they will be sent an invitation letter and PIS. The PIS will include 
a reply slip to enable participants to register their interest in taking part and to opt in to 
receiving contact from the researcher. Participants will be informed that once their reply slip 
has been received, the Chief Investigator will contact them by telephone to discuss the study 
further and to arrange an appointment.  
Procedure 
Once participants have agreed to be contacted, the Chief Investigator will contact them by 
telephone to discuss the study further and to arrange an interview appointment. All 
appointments will take place at NHS Lothian sites, at the Royal Edinburgh Hospital, 
Edinburgh, at St. John's Hospital, Livingston, at Musselburgh Primary Care Centre, 
Musselburgh, at Herdmanflat Hospital, Haddington, or in their own homes (only if this 
assessed as safe). Home visits will only be offered to those participants who are known to the 
NHS clinician (Psychology, Psychiatry, Nursing) who identifies that the patient meets 
inclusion criteria, and where the clinician has no concerns regarding risk to NHS staff lone 
workers. In the case of patients identified via casenote review, the possibility of home visits 
will be discussed with the project supervisor and with the patient's named clinician. For these 
participants, home visits will only be offered where no concerns are raised regarding risk to 
NHS staff lone workers. The NHS Lothian Lone Worker policy and the department’s own 
Safe and Well procedures will be followed at all times in order to minimise any potential risk 
during home visits.  
Interview appointments will last approximately one hour. Each appointment will consist of 
the following: 
 Seeking informed consent (5 minutes) 
 Completion of demographic questionnaire (5 minutes) 
 Completion of cognitive screening measure – those scoring below clinical cut off for 
dementia on the MoCA will be removed from the study and their GP informed (10 
minutes) 
 Assessment of mood (5 minutes) 
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 Assessment of anxiety (5 minutes) 
 Assessment of illness appraisals (10 minutes) 
 Assessment of PF (5 minutes) 
 Assessment of QoL (10 minutes) 
 Participant questions/comments and debrief (5 minutes) 



























Should participants wish to take a short break, they will be offered the opportunity to do so. 
If participants become distressed or feel fatigued, they will have the option of rescheduling 
the appointment or discontinuing their involvement in the study. Appropriate steps will be 
taken to minimise risk of harm should participants report distress. The Chief Investigator, as 
a Trainee Clinical Psychologist, is competent in the core skills necessary to provide 
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immediate comfort and psychological support, and participants will be advised to seek 
further advice from their GP should they have any concerns about their mental and/or 
cognitive health. If significant concerns are raised regarding a participant's mental health, the 
Chief Investigator will seek advice from the project clinical supervisor and will provide 
immediate support, the participant's GP will be informed and they will be removed from the 
study. The Chief Investigator will be working under the supervision of a qualified Clinical 
Psychologist, and will be able to seek further advice from them if necessary. In addition, as 
part of the clinical team, the Chief Investigator will be able to facilitate access to 
psychological support and other treatments from the wider Older Adult Mental Health 
Service for participants if necessary. 
Statistical Analysis 
Initial correlational analyses will be carried out in order to establish the relationships 
between variables in the statistical model. Any variables not correlated will be removed from 
the model. The main research questions and objectives will be examined through mediation 
analysis, calculated using bias-corrected bootstrapping techniques, with separate analyses 
being carried out for each independent and dependent variable. Therefore, a total of six 
mediation analyses will be calculated. The independent variables are: level of cognitive 
impairment and illness perceptions. The mediator variable is PF, and the dependent variables 
are: QoL, depression and anxiety. 
Dissemination 
The study will be written up as a doctoral thesis in line with the requirements of the 
University of Edinburgh Doctorate in Clinical Psychology. The thesis will also include a 
write up of the study in peer-reviewed journal format which will be prepared for publication 
in a relevant journal. A brief summary of the findings of the study will also be compiled and 
sent out to any participants who indicated their interest in receiving this on the consent form. 
Presentations will also be delivered to interested stakeholders and at relevant conferences 
and CPD events. 
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PARTICIPANT INFORMATION SHEET 
 
 
STUDY TITLE: Psychological adjustment to mild cognitive impairment 
You are being invited to take part in a research study. Before you decide if you would like to 
participate, it is important for you to understand why the research is being done and what it would 
involve for you. Please take time to read the following information carefully, and talk to others 
about the study if you wish. If there is anything that is unclear, or if you have any questions, please 
do not hesitate to ask the Chief Investigator (Amanda Stevenson). You can also contact them using 
the details at the end of this sheet. 
 
WHAT IS THE RESEARCH ABOUT? 
This study is examining how people adjust to receiving a diagnosis of mild cognitive 
impairment (sometimes referred to as memory and thinking difficulties). We know that how 
people view their diagnosis or condition can affect their sense of wellbeing, but the ways in 
which psychological factors influence the relationship between views about a condition and 
wellbeing are not well understood.  
 
WHY HAVE I BEEN INVITED? 
We are inviting people who have received a diagnosis of mild cognitive impairment within the 
past nine months to take part. We are aiming to recruit between 50 and 60 participants. 
 
DO I HAVE TO TAKE PART? 
No. It is up to you to decide whether or not to join this study.  
 
If you do decide to participate, you will be asked to sign a consent form, and you will be able 
to keep this information sheet for reference. If you decide to take part you will still be able to 
withdraw from the study at any point and you do not have to give a reason.  
 
Involvement with the study will not affect the care you receive from any NHS service, now, 




WHAT WILL HAPPEN TO ME IF I TAKE PART? 
If you choose to take part in this study, you will be asked to meet with the Chief Investigator 
on one occasion to participate in an individual interview lasting approximately one hour. The 
appointment will take place at one of the following locations: Royal Edinburgh Hospital, 
Edinburgh; St John's Hospital, Livingston; Musselburgh Primary Care Centre, Musselburgh; 
Herdmanflat Hospital, Haddington. We may be able to offer to visit you at home, in specific 
circumstances. You will be able to choose which one would be most convenient for you, along 
with a time and date which is suitable for you. Please note that unfortunately we are unable to 
reimburse your travel expenses.  
 
During the appointment you will have a further opportunity to ask questions and to discuss 
your involvement in the study. If you still wish to participate, you will be asked to sign a 
consent form stating that you agree to participate and that you understand what your 
participation will entail. We will also inform your GP (General Practitioner) by letter that you 
are taking part in the study.  
 
You will then be asked to complete a series of questionnaires with the assistance of the Chief 
Investigator including: 
 
 A brief test of mental functioning, such as memory 
 Your views regarding your diagnosis of mild cognitive impairment and your current 
mental health 
 
If at any point during the appointment you no longer wish to take part, you may withdraw from 
the study without having to give a reason. 
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
It is likely that there will not be an immediate benefit to you, but your participation will aid in 
our understanding of how people adjust to mild cognitive impairment. This may inform the 
development of future psychological treatments and interventions for people with mild 
cognitive impairment.  
 
WHAT ARE THE POSSIBLE RISKS AND DISADVANTAGES OF TAKING PART? 
You will be asked to complete a set of seven tasks and questionnaires over a period of 
approximately one hour, which can leave some people feeling tired. In addition, some 
questions will ask you about sensitive topics, particularly regarding your current mental health, 
and your views about your diagnosis of mild cognitive impairment. It is possible that thinking 




If you should experience either of these then you should inform the Chief Investigator, who 
will offer you support and ask whether you would like to take a break or to reschedule a later 
appointment. If you should become upset, or have any concerns, the Chief Investigator will be 
able to provide you with immediate comfort and support. We may also need to inform your 
GP or involve someone else who can help, such as a Psychiatrist. 
 
WHAT HAPPENS WHEN THE RESEARCH STUDY STOPS? 
Consent forms and identifiable information will be destroyed, but your anonymous data may 
be held for future authorised research.  
 
WILL MY TAKING PART IN THE STUDY BE KEPT CONFIDENTIAL? 
All the information we collect from you will be kept confidential. We will keep your data 
anonymous during the research by assigning it a unique reference number. This reference 
number will be the only link between your data and your consent form. Once the study has 
been completed, your consent form will be destroyed. Your data will be securely stored on an 
NHS site and will be kept separately from consent forms. 
 
Your data will only be accessible to the Chief Investigator, study supervisors, and anyone 
appointed by the Sponsor (NHS Lothian/University of Edinburgh) to ensure the study is being 
carried out correctly. 
 
We will inform your GP of your participation in the study by letter; however, we will not 
provide details to your GP regarding your performance on the assessment task or of your 
responses to questionnaires, unless you report any significant difficulties with your mood or 
functioning.  
 
If you report anything that makes the Chief Investigator consider that you, or someone you 
know, are at risk of harm, your GP would need to be informed and we may need to involve 
someone else who can help, such as a Psychiatrist. Similarly, if you report information that 
relates to the prevention or detection of crime, the Chief Investigator may be required to 
disclose this information to relevant agencies (eg. Police). In each case, the Chief Investigator 
would discuss with you how this might be addressed. 
  
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? 
The results of the study will be written up and reported in a doctoral thesis format in part 
fulfilment of the requirements of the University of Edinburgh Doctorate in Clinical 
Psychology. We also hope to submit this thesis project to relevant academic journals for 
publication. All the information we collect from you will be kept anonymous, and will only 




If you would like to be informed of the results of the study, you may indicate your preference 
when signing the study consent form. You will then be provided with a written summary 
following completion of the study in May 2014. 
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
The study is being organised by Amanda Stevenson, Trainee Clinical Psychologist, under the 
supervision of Dr. David Gillanders (University of Edinburgh), Dr. Nuno Ferreira (University 
of Edinburgh) and Dr. Donna Gilroy (NHS Lothian). The study is being supported by both 
NHS Lothian and the University of Edinburgh.  
 
WHO HAS REVIEWED THE STUDY? 
The project proposal has been reviewed and accepted by the University of Edinbugh Doctorate 
in Clinical Psychology, and by my supervisors: Dr. David Gillanders (Academic Director, 
Doctorate in Clinical Psychology), Dr. Nuno Ferreira (Lecturer in Clinical Psychology) and 
Dr. Donna Gilroy (Clinical Psychologist). Ethical approval has been granted by South East 
Scotland Research Ethics Committee on 21/01/14. 
 
WHAT TO DO NOW? 
Since you have indicated to a member of staff that you are interested in participating, the Chief 
Investigator will contact you by telephone in the coming weeks to discuss the study with 
you and to arrange an interview appointment.  
 
Alternatively, you may contact the Chief Investigator using the below details: 
 
Amanda Stevenson 
Trainee Clinical Psychologist 
Older Adult Psychology Service 






If you would like to speak to someone else about the study, please contact: 
 
Dr Heather Wilkinson 
Research Director 
School of Health in Social Science 







WHAT IF SOMETHING GOES WRONG? 
If you should wish to make a formal complaint regarding the study, please contact:  
 
NHS Lothian Complaints Team 
Waverley Gate 
2nd Floor 
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 

























Fig. 1: Flow chart explaining participation process 
 
Thank you for taking the time to read this information sheet 
Amanda Stevenson, Trainee Clinical Psychologist 
 







Amanda Stevenson will contact you by 
telephone to ask you if you if you would 
like to discuss the study further and to 
ask you if you would like to participate
I do not wish to participate: You 
may inform Amanda Stevenson at 
this point. You do not need to do 
anything else.
I would like to discuss the study 
further or would like to discuss 
how I can participate: You may ask 
Amanda Stevenson any questions 
you wish at this point.
I would like to 
participate
Arrange a time, date and location 
to complete the interview 
appointment. Your GP will be 




I do not wish to 
participate: Please inform 
Amanda Stevenson that 
you no longer wish to take 
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PARTICIPANT INFORMATION SHEET 
 
STUDY TITLE: Psychological adjustment to mild cognitive impairment 
You are being invited to take part in a research study. Before you decide if you would like to 
participate, it is important for you to understand why the research is being done and what it would 
involve for you. Please take time to read the following information carefully, and talk to others 
about the study if you wish. If there is anything that is unclear, or if you have any questions, please 
do not hesitate to ask the Chief Investigator (Amanda Stevenson). You can also contact them using 
the details at the end of this sheet. 
 
WHAT IS THE RESEARCH ABOUT? 
This study is examining how people adjust to receiving a diagnosis of mild cognitive 
impairment (sometimes referred to as memory and thinking difficulties). We know that how 
people view their diagnosis or condition can affect their sense of wellbeing, but the ways in 
which psychological factors influence the relationship between views about a condition and 
wellbeing are not well understood.  
 
WHY HAVE I BEEN INVITED? 
We are inviting people who have received a diagnosis of mild cognitive impairment within the 
past three to six months to take part. We are aiming to recruit between 50 and 60 participants. 
 
DO I HAVE TO TAKE PART? 
No. It is up to you to decide whether or not to join this study.  
 
If you do decide to participate, you will be asked to sign a consent form, and you will be able 
to keep this information sheet for reference. If you decide to take part you will still be able to 
withdraw from the study at any point and you do not have to give a reason.  
 
Involvement with the study will not affect the care you receive from any NHS service, now, 
or in the future (whether or not you decide to participate). 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
If you choose to take part in this study, you will be asked to meet with the Chief Investigator 
on one occasion to participate in an individual interview lasting approximately one hour. The 
appointment will take place at one of the following locations: Royal Edinburgh Hospital, 
Edinburgh; St John's Hospital, Livingston; Musselburgh Primary Care Centre, Musselburgh; 
Herdmanflat Hospital, Haddington. We may be able to offer to visit you at home, in specific 
circumstances. You will be able to choose which one would be most convenient for you, along 
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with a time and date which is suitable for you. Please note that unfortunately we are unable to 
reimburse your travel expenses.  
 
During the appointment you will have a further opportunity to ask questions and to discuss 
your involvement in the study. If you still wish to participate, you will be asked to sign a 
consent form stating that you agree to participate and that you understand what your 
participation will entail. We will also inform your GP (General Practitioner) by letter that you 
are taking part in the study.  
 
You will then be asked to complete a series of questionnaires with the assistance of the Chief 
Investigator including: 
 
 A brief test of mental functioning, such as memory 
 Your views regarding your diagnosis of mild cognitive impairment and your current 
mental health 
 
If at any point during the appointment you no longer wish to take part, you may withdraw from 
the study without having to give a reason. 
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
It is likely that there will not be an immediate benefit to you, but your participation will aid in 
our understanding of how people adjust to mild cognitive impairment. This may inform the 
development of future psychological treatments and interventions for people with mild 
cognitive impairment.  
 
WHAT ARE THE POSSIBLE RISKS AND DISADVANTAGES OF TAKING PART? 
You will be asked to complete a set of seven tasks and questionnaires over a period of 
approximately one hour, which can leave some people feeling tired. In addition, some 
questions will ask you about sensitive topics, particularly regarding your current mental health, 
and your views about your diagnosis of mild cognitive impairment. It is possible that thinking 
about these issues may cause some to feel upset or distressed.  
 
If you should experience either of these then you should inform the Chief Investigator, who 
will offer you support and ask whether you would like to take a break or to reschedule a later 
appointment. If you should become upset, or have any concerns, the Chief Investigator will be 
able to provide you with immediate comfort and support. We may also need to inform your 
GP or involve someone else who can help, such as a Psychiatrist. 
 
WHAT HAPPENS WHEN THE RESEARCH STUDY STOPS? 
Consent forms and identifiable information will be destroyed, but your anonymous data may 
be held for future authorised research.  
 
WILL MY TAKING PART IN THE STUDY BE KEPT CONFIDENTIAL? 
All the information we collect from you will be kept confidential. We will keep your data 
anonymous during the research by assigning it a unique reference number. This reference 
number will be the only link between your data and your consent form. Once the study has 
been completed, your consent form will be destroyed. Your data will be securely stored on an 
NHS site and will be kept separately from consent forms. 
 
Your data will only be accessible to the Chief Investigator, study supervisors, and anyone 
appointed by the Sponsor (NHS Lothian/University of Edinburgh) to ensure the study is being 




We will inform your GP of your participation in the study by letter; however, we will not 
provide details to your GP regarding your performance on the assessment task or of your 
responses to questionnaires, unless you report any significant difficulties with your mood or 
functioning.  
 
If you report anything that makes the Chief Investigator consider that you, or someone you 
know, are at risk of harm, your GP would need to be informed and we may need to involve 
someone else who can help, such as a Psychiatrist. Similarly, if you report information that 
relates to the prevention or detection of crime, the Chief Investigator may be required to 
disclose this information to relevant agencies (eg. Police). In each case, the Chief Investigator 
would discuss with you how this might be addressed. 
  
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? 
The results of the study will be written up and reported in a doctoral thesis format in part 
fulfilment of the requirements of the University of Edinburgh Doctorate in Clinical 
Psychology. We also hope to submit this thesis project to relevant academic journals for 
publication. All the information we collect from you will be kept anonymous, and will only 
be identifiable to the Chief Investigator and study supervisors. 
 
If you would like to be informed of the results of the study, you may indicate your preference 
when signing the study consent form. You will then be provided with a written summary 
following completion of the study in August 2014. 
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
The study is being organised by Amanda Stevenson, Trainee Clinical Psychologist, under the 
supervision of Dr. David Gillanders (University of Edinburgh), Dr. Nuno Ferreira (University 
of Edinburgh) and Dr. Donna Gilroy (NHS Lothian). The study is being supported by both 
NHS Lothian and the University of Edinburgh.  
 
WHO HAS REVIEWED THE STUDY? 
The project proposal has been reviewed and accepted by the University of Edinbugh Doctorate 
in Clinical Psychology, and by my supervisors: Dr. David Gillanders (Academic Director, 
Doctorate in Clinical Psychology), Dr. Nuno Ferreira (Lecturer in Clinical Psychology) and 
Dr. Donna Gilroy (Clinical Psychologist). Ethical approval has been granted by South East 
Scotland Research Ethics Committee 2 on 21/01/14. 
 
WHAT TO DO NOW? 
If you would like to know more about the study or are interested in participating, please contact 
the Chief Investigator using the reply slip at the end of this sheet. Amanda Stevenson will then 
contact you by telephone to discuss the study with you and to arrange an appointment should 
you decide to participate. 
 
FURTHER INFORMATION 
If you would like to speak to someone else about the study, please contact: 
 
Dr Heather Wilkinson 
Research Director 
School of Health in Social Science 







WHAT IF SOMETHING GOES WRONG? 
 
If you should wish to make a formal complaint regarding the study, please contact:  
 
NHS Lothian Complaints Team 
Waverley Gate 
2nd Floor 
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 






























Thank you for taking the time to read this information sheet 
 











Contact Amanda Stevenson using above 
details or complete the reply slip and 
send to the above address.
Amanda Stevenson will contact you by 
telephone to discuss the study further with 
you.
I would like to 
participate
Arrange a time, date and location 
to complete the interview 
appointment. Your GP will be 




I do not wish to 
participate: Please inform 
Amanda Stevenson that 
you no longer wish to take 
part. You do not have to 
provide a reason.
I would like further information or 
would like to discuss how I can 
participate in the study.
I do not wish to 
participate.
You do not need to do 
anything else. Thank you 




If you would like to participate in the study, or would like a researcher to contact you 
to discuss the study, please complete the tear off slip below and send it to: 
 
Amanda Stevenson 
Trainee Clinical Psychologist 
Older Adult Psychology Service 
Psychology Department 
St John’s Hospital 
Livingston 
West Lothian 
EH54 6PP 
 
 
 
 
 
 
 
 
 
